



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/58, 31/56, C07J 43/00, 41/00	A1	(11) International Publication Number: WO 95/21617 (43) International Publication Date: 17 August 1995 (17.08.95)
(21) International Application Number: PCT/US95/01712 (22) International Filing Date: 14 February 1995 (14.02.95) (30) Priority Data: 08/196,919 14 February 1994 (14.02.94) US 08/346,927 23 November 1994 (23.11.94) US (71) Applicant: COCENSYS, INC. [US/US]; 213 Technology Drive, Irvine, CA 92718 (US). (72) Inventors: UPASANI, Ravindra, B.; 63 Montecilo, Foothill Ranch, CA 92610 (US). XIA, Haiji; 26 Pastora, Foothill Ranch, CA 92610 (US). HOGENKAMP, Derk; 3929 Elm Avenue, Long Beach, CA 90807 (US). (74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR (57) Abstract Methods, compositions, and compounds for modulating the GABA _A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LY	Libya	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

Androstanes and Pregnanes for Allosteric Modulation of GABA Receptor

Cross Reference to Related Applications

5. This application is a continuation-in-part of U.S. Serial No. 08/346,927, filed November 23, 1994, which is a continuation-in-part of U.S. Serial No. 08/196,919, filed February 14, 1994, the contents of each of which is fully incorporated by reference herein.

Background of the Invention

10 The present invention is directed to methods, compositions, and compounds for modulating animal (and human) brain excitability via the gamma-aminobutyric acid A (GABA_A) receptor-chloride ionophore complex (GRC). Specifically, the present invention is directed to methods, compositions, and compounds for modulating brain excitability through
15 binding to the neurosteroid receptor site on the GRC.

Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters. In general, neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes. At rest, the neuronal
20 membrane possesses a potential (or membrane voltage) of approximately -80 mV, the cell interior being negative with respect to the cell exterior. The potential (voltage) is the result of ion (K⁺, Na⁺, Cl⁻, organic anions) balance across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released under the influence of neuronal action
25 potentials. When released into the synaptic cleft, an excitatory chemical transmitter such as acetylcholine will cause membrane depolarization (change of potential from -80 mV to -50 mV). This effect is mediated by postsynaptic nicotinic receptors which are stimulated by acetylcholine to increase membrane

-2-

permeability to Na^+ ions. The reduced membrane potential stimulates neuronal excitability in the form of a postsynaptic action potential.

In the case of the GRC, the effect on brain excitability is mediated by GABA, a neurotransmitter. GABA has a profound influence on overall brain excitability because up to 40% of the neurons in the brain utilize GABA as a neurotransmitter. GABA regulates the excitability of individual neurons by regulating the conductance of chloride ions across the neuronal membrane. GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell. An intracellular increase in the levels of this anion causes hyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs (i.e., reduced neuron excitability). In other words, the higher the chloride ion concentration in the neuron, the lower the brain excitability (the level of arousal).

It is well-documented that the GRC is responsible for the mediation of anxiety, seizure activity, and sedation. Thus, GABA and drugs that act like GABA or facilitate the effects of GABA (e.g., the therapeutically useful barbiturates and benzodiazepines (BZs) such as Valium) produce their therapeutically useful effects by interacting with specific regulatory sites on the GRC.

It has also been observed that a series of steroid metabolites interact with the GRC to alter brain excitability (Majewska, M.D. *et al.*, "Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor," *Science* 232:1004-1007 (1986); Harrison, N.L. *et al.*, Structure-activity relationships for steroid interaction with the gamma-aminobutyric acid-A receptor complex," *J. Pharmacol. Exp. Ther.* 241:346-353 (1987)). Prior to the present invention, the therapeutic usefulness of these steroid metabolites was not recognized by workers in the field due to an incomplete understanding of the potency and site of action. Applicants' invention relates in part to a pharmaceutical application of the knowledge gained from a more developed understanding of the potency and site of action of certain steroid compounds.

The ovarian hormone progesterone and its metabolites have been demonstrated to have profound effects on brain excitability (Backstrom, T. *et al.*, "Ovarian steroid hormones: effects on mood, behavior and brain excitability," *Acta Obstet. Gynecol. Scand. Suppl.* 130:19-24 (1985); Pfaff, D.W. and McEwen, B.S., "Actions of estrogens and progestins on nerve cells," *Science* 219:808-814 (1983); Gyermek *et al.*, "Structure activity relationship of some steroidal hypnotic agents," *J. Med. Chem.* 11:117 (1968); Lambert, J. *et al.*, "Actions of synthetic and endogenous steroids on the GABA_A receptor," *Trends Pharmacol.* 8:224-227 (1987)). The levels of progesterone and its metabolites vary with the phases of the menstrual cycle. It has been well documented that progesterone and its metabolites decrease prior to the onset of menses. The monthly recurrence of certain physical symptoms prior to the onset of menses has also been well documented. These symptoms, which have become associated with premenstrual syndrome (PMS) include stress, anxiety, and migraine headaches (Dalton, K., *Premenstrual Syndrome and Progesterone Therapy*, 2nd edition, Chicago: Chicago yearbook, 1984). Patients with PMS have a monthly recurrence of symptoms that are present in premenses and absent in postmenses.

In a similar fashion, a reduction in progesterone has also been temporally correlated with an increase in seizure frequency in female epileptics (i.e., catamenial epilepsy; Laidlaw, J., "Catamenial epilepsy," *Lancet*, 1235-1237 (1956)). A more direct correlation has been observed with a reduction in progesterone metabolites (Roszczewska *et al.*, "Ovarian hormones, anticonvulsant drugs and seizures during the menstrual cycle in women with epilepsy," *J. Neurol. Neurosurg. Psych.* 49:47-51 (1986)). In addition, for patients with primary generalized petit mal epilepsy, the temporal incidence of seizures has been correlated with the incidence of the symptoms of premenstrual syndrome (Backstrom, T. *et al.*, "Endocrinological aspects of cyclical mood changes during the menstrual cycle or the premenstrual syndrome," *J. Psychosom. Obstet. Gynaecol.* 2:8-20 (1983)). The steroid deoxycorticosterone has been found to be effective in treating patients with

epileptic spells correlated with their menstrual cycles (Aird, R.B. and Gordan, G., "Anticonvulsive properties of deoxycorticosterone," *J. Amer. Med. Soc.* 145:715-719 (1951)).

5 A syndrome also related to low progesterone levels is postnatal depression (PND). Immediately after birth, progesterone levels decrease dramatically leading to the onset of PND. The symptoms of PND range from mild depression to psychosis requiring hospitalization; PND is associated with severe anxiety and irritability. PND-associated depression is not amenable to treatment by classic antidepressants and women experiencing PND show an
10 increased incidence of PMS (Dalton, K., 1984).

Collectively, these observations imply a crucial role for progesterone and deoxycorticosterone and more specifically their metabolites in the homeostatic regulation of brain excitability, which is manifested as an increase in seizure activity or symptoms associated with catamenial epilepsy, PMS, and
15 PND. The correlation between reduced levels of progesterone and the symptoms associated with PMS, PND, and catamenial epilepsy (Backstrom *et al.*, 1983; Dalton, K., 1984) has prompted the use of progesterone in their treatment (Mattson *et al.*, "Medroxyprogesterone therapy of catamenial epilepsy," in *Advances in epileptology: XVth Epilepsy International Symposium*, Raven Press, New York, 279-282, 1984, and Dalton, K., 1984).
20 However, progesterone is not consistently effective in the treatment of the aforementioned syndromes. For example, no dose-response relationship exists for progesterone in the treatment of PMS (Maddocks, *et al.*, "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment
25 of premenstrual syndrome," *Obstet. Gynecol.* 154:573-581 (1986); Dennerstein, *et al.*, *British Medical Journal*, 290:16-17 (1986)).

The publications and references referred to above and hereafter in this specification are incorporated herein by reference.

Summary of the Invention

The present invention is directed to methods, compositions, and compounds for modulating brain excitability. More particularly, the invention relates to the use of 3α -hydroxylated steroid derivatives, acting at a newly identified site on the GR complex, to modulate brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders (such as depression) that are amenable to GR-active agents, and seizure activity. Compositions and compounds effective for such treatment are within the scope of the invention.

The compounds used in and forming part of the invention are modulators of the excitability of the central nervous system as mediated by their ability to regulate chloride ion channels associated with the GABA_A receptor complex. Applicants' experiments have established that the compounds used in and of the invention have anticonvulsant and anxiolytic activity similar to the actions of known anxiolytic agents such as the BZs, but act at a distinct site on the GR complex.

The relationship of endogenous metabolites of progesterone to processes associated with reproduction (estrus cycle and pregnancy) is well established (Marker, R.E., Kamm, O., and McGrew, R.V., "Isolation of epi-pregnanol-3-one-20 from human pregnancy urine," *J. Am. Chem. Soc.* 59:616-618 (1937)). Prior to the present invention, however, it was not recognized how to treat disorders by modulating brain excitability through the use of progesterone metabolites and their derivatives. Therefore, this invention is directed to methods, compositions, and compounds to treat disorders by modulating brain excitability using the compounds of this invention. Representative disorders treated in the present invention are epilepsy, anxiety, pre-menstrual syndrome (PMS), post-natal depression (PND), mood disorders (such as depression) that are amenable to GR-active agents, and insomnia. The compounds of the invention can also be used to induce anesthesia.

Brief Description of the Drawings

The present invention may be better understood and its advantages appreciated by those skilled in the art by referring to the accompanying drawings wherein:

5 FIGS. 1A and 1B are plots of the percent binding of [35 S] t-butylbicyclophosphorothionate ([35 S] TBPS) to the cell membranes of rat brain vs. log concentration of the alphaxalone (also called alfaxalone) and GABA in various concentrations of (+)bicuculline.

10 FIG. 2 shows time courses for the dissociation of 2 nM [35 S] TBPS from rat cortical P_2 homogenates initiated by the addition of 2 μ M TBPS (\blacksquare), 1 μ M $3\alpha,5\alpha$ P (\square), 100 μ M Na pentobarbital (\bullet), and 1 μ M $3\alpha,5\alpha$ P + 100 μ M Na pentobarbital (\circ).

15 FIG. 3 is a plot showing the effect of a single dosage of pentobarbital on 3α -OH- 5α -pregnan-20-one ($3\alpha,5\alpha$ -P) modulation of [3 H]-flunitrazepam binding in rat hippocampal homogenates.

 FIG. 4 is a plot of the effect of 3α -hydroxy- 5α -pregnan-20-one, $3\alpha,21$ -dihydroxy- 5α -pregnan-20-one (5α -THDOC) and R5020 (promegesterone) on inhibiting [35 S] TBPS binding in rat cerebral cortex homogenate.

20 FIG. 5 is a plot of the correlation between TBPS binding and electrophysiological activity of 15 different 3α -hydroxylated steroids.

 FIG. 6 is a plot of the effect of 3α -OH- 5α -pregnan-20-one, 5α -pregnan- $3\alpha,20\alpha$ -diol and 5β -pregnan- $3\alpha,20\beta$ -diol on inhibiting [35 S] TBPS binding in rat cortex homogenate.

25 FIG. 7 is a plot showing the effect of 3α -OH- 5α -pregnan-20-one, 5α -pregnan- $3\alpha,20\alpha$ -diol, and 5β -pregnan- $3\alpha,20\beta$ -diol on the GABA-evoked current in *Xenopus* oocytes injected with human recombinant GABA receptor subunit $\alpha 1\beta 1\gamma 2L$.

30 FIG. 8 is a line graph of the number of transitions from light to dark occurring within ten minutes of injection of 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one.

-7-

FIG. 9A and 9B are two line graphs of the percentage of (A) entries into and (B) the time on the open-arms during a five-minute test period of 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one in the elevated plus-maze test.

5 FIG. 10 is a line graph of the change in punished rats responding from baseline for 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one in the Geller Seifter test.

FIG. 11 is a plot of the time course of anti-metrazol activity of several prodrugs of 3α -OH- 5α -pregnan-20-one.


10 ***Detailed Description of the Preferred Embodiments***

The compounds of and used in the invention are derivatives of various 3α -hydroxylated-pregnanes and 3α -hydroxylated-androstanes, and ester, ether, sulfonate, sulfate, phosphonate, phosphate, oxime, thiosulfate, heterocyclic and heteroaryl derivatives thereof, and derivatives referred to as prodrugs. The expression "prodrug" denotes a derivative of a known direct acting drug, which derivative has enhanced delivery characteristics and therapeutic value as compared to the drug, and is transformed into the active drug by an enzymatic or chemical process; see Notari, R.E., "Theory and Practice of Prodrug Kinetics," *Methods in Enzymology*, 112:309-323 (1985); Bodor, N., "Novel Approaches in Prodrug Design," *Drugs of the Future*, 6(3):165-182 (1981); and Bundgaard, H., "Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities," in *Design of Prodrugs* (H. Bundgaard, ed.), Elsevier, New York (1985). It should be noted that some of the synthetic derivatives forming part of the present invention may not be true prodrugs because, in addition to the above characteristics, they also possess intrinsic activity. However, for purposes of this application they will be referred to as prodrugs.

Our studies (Gee, K.W. *et al.*, "GABA-dependent modulation of the Cl ionophore by steroids in rat brain," *European Journal of Pharmacology*,

136:419-423, 1987) have demonstrated that the 3 α -hydroxylated steroids used in the invention are orders of magnitude more potent than others have reported (Majewska, M.D. *et al.* (1986) and Harrison, N.L. *et al.* (1987)) as modulators of the GR complex. Majewska *et al.* and Harrison *et al.* teach that the 3 α -hydroxylated-5-reduced steroids are only capable of much lower levels of effectiveness. Our *in vitro* and *in vivo* experimental data demonstrate that the high potency of these steroids allows them to be therapeutically useful in the modulation of brain excitability via the GR complex. The most potent steroids useful in the present invention include derivatives of major metabolites of progesterone and deoxycorticosterone. These steroids can be specifically used to modulate brain excitability in stress, anxiety, insomnia, mood disorders (such as depression) that are amenable to GR-active agents, and seizure disorders in a therapeutically beneficial manner. Furthermore, we have demonstrated that these steroids interact at a unique site on the GR complex which is distinct from other known sites of interaction (i.e., barbiturate, BZ, and GABA) where therapeutically beneficial effects on stress, anxiety, sleep, mood disorders and seizure disorders have been previously elicited (Gee, K.W. and Yamamura, H.I., "Benzodiazepines and Barbiturates: Drugs for the Treatment of Anxiety, Insomnia and Seizure Disorders," in *In Central Nervous System Disorders*, pages 123-147, D.C. Horvell, ed., 1985; Lloyd, K.G. and Morselli, P.L., "Psychopharmacology of GABAergic Drugs," in *Psychopharmacology: The Third Generation of Progress*, pages 183-195, H.Y. Meltzer, ed., Raven Press, N.Y., 1987). These compounds are desirable for their duration, potency and oral activity (along with other forms of administration).

The steroid derivatives of this invention are those having one of the following structural formula (I):



wherein R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are further defined herein and the dotted lines are single or double bonds. The structure having Formula I includes androstanes, pregnanes (R₄ = methyl), 19-nor-androstanes, and norpregnanes (R₄ = H).

The present invention also includes pharmaceutically acceptable esters and salts of the compounds of Formula I, including acid addition salts. It is believed that the 3 α -hydroxyl may also be masked as a pharmaceutically acceptable ester due to the fact that the ester will be cleaved off as the prodrug is converted to drug form. These are referred to herein as cleavable esters.

Definitions

In accordance with the present invention and as used herein, the following terms are defined with the following meaning, unless explicitly stated otherwise.

The term "alkyl" refers to saturated aliphatic groups including straight chain, branched chain, and cyclic groups, all of which may be optionally substituted. Suitable alkyl groups include methyl, ethyl, and the like, and may be optionally substituted.

The term "alkenyl" refers to unsaturated groups which contain at least one carbon-carbon double bond and includes straight chain, branched chain, and cyclic groups, all of which may be optionally substituted.

5 The term "alkynyl" refers to unsaturated hydrocarbon groups which contain at least one carbon-carbon triple bond and includes straight chain and branched chain groups which may be optionally substituted. Suitable alkynyl groups include propynyl, pentynyl, and the like which may be optionally substituted with cyano, acetoxy, halo, hydroxy or keto. Preferred alkynyl groups have five to eighteen carbon atoms. More preferred alkynyl groups have five to twelve carbon atoms. Most preferred alkynyl groups have five to seven carbon atoms.

The term "alkoxy" refers to the ether -OR wherein R is alkyl.

The term "aryloxy" refers to the ether -OR wherein R is aryl.

15 The term "aryl" refers to aromatic groups which have at least one ring having a conjugated pi electron system and includes carbocyclic aryl and biaryl, both of which may be optionally substituted.

The term "carbocyclic aryl" refers to groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include phenyl and naphthyl groups optionally substituted. Substituted phenyl has preferably one to three, four or five substituents, such being advantageously, lower alkyl, amino, amido, cyano, carboxylate ester, hydroxy, lower alkoxy, halogen, lower acyl, and nitro.

20 The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, and the like, and may be optionally substituted.

The term "alkanoyloxy" refers to -O-C(O)R, wherein R is alkyl, alkenyl, alkynyl, aryl or aralkyl.

The term "carbalkoxyl" refers to -C(O)OR, wherein R is alkyl, alkenyl, alkynyl, aryl or aralkyl.

30 The term "carboxamido" refers to -C(O)NRR₁, wherein R and R₁ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl or aralkyl.

The term "dialkylamino" refers to -NRR" where R and R" are independently lower alkyl groups or together form the rest of a morpholino group. Suitable dialkylamino groups include dimethyl amino, diethylamino, and morpholino.

5 The term "acyl" refers to the alkanoyl group -C(O)R where R is alkyl, alkenyl, alkynyl, aryl, or aralkyl.

The term "amino" refers to NRR', wherein R and R' are independently hydrogen, lower alkyl or are joined together to give a 5 or 6-membered ring, e.g. pyrrolidine or piperidine rings.

10 The term "optionally substituted" or "substituted" refers to groups substituted by one to three, four or five substituents, independently selected from lower alkyl (acyclic and cyclic), aryl (carboaryl and heteroaryl), alkenyl, alkynyl, alkoxy, halo, haloalkyl (including trihaloalkyl, e.g. trifluoromethyl), amino, mercapto, alkylthio, alkylsulfinyl, alkylsulfonyl, nitro, alkanoyl, alkanoyloxy, alkanoyloxyalkanoyl, alkoxycarboxy, carbalkoxy (-COOR, 15 wherein R is lower alkyl), carboxamido (-CONRR', wherein R and R' are independently lower alkyl), formyl, carboxyl, hydroxy, cyano, azido, keto and cyclic ketals thereof, alkanoylamido, heteroaryloxy, heterocarbocyclicoxy, and hemisuccinate ester salts.

20 The term "lower" is referred to herein in connection with organic radicals or compounds defines such as one up to and including ten, preferably up to and including six, and advantageously one to four carbon atoms. Such groups may be straight chain, branched chain, or cyclic.

25 The term "heterocyclic" refers to carbon containing radicals having four, five, six, or seven membered rings and one, two or three O, N or S heteroatoms, e.g., thiazolidine, tetrahydrofuran, 1,4-dioxane, pyrrolidine, piperidine, quinuclidine, dithiane, tetrahydropyran, ϵ -caprolactone, ϵ -caprolactam, ω -thiocaprolactam, and morpholine.

30 The term "heteroaryl" refers to carbon containing 5-14 membered cyclic unsaturated radicals containing one, two, three or four O, N or S atoms and having 6, 10 or 14 π electrons delocalized in one or more rings, e.g.,

pyridine, oxazole, indole, purine, pyrimidine, imidazole, benzimidazole, indazole, 2*H*-1,2,4-triazole, 1,2,3-triazole, 2*H*-1,2,3,4-tetrazole, 1*H*-1,2,3,4-tetrazole, benzotriazole, 1,2,3-triazolo[4,5-*b*]pyridine, thiazole, isoxazole, pyrazole, quinoline, cytosine, thymine, uracil, adenine, guanine, pyrazine, picolinic acid, picoline, furoic acid, furfural, furyl alcohol, carbazole, 9*H*-pyrido[3,4-*b*]indole, isoquinoline, pyrrole, thiophene, furan, 9(10*H*)-acridone, phenoxazine, and phenothiazine, each of which may be optionally substituted as discussed above.

The term "dioic acids" refers to C₁₋₅ alkylene groups substituted with two carboxy groups, for example, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, and suberic acid. Hemi-ester salts of the dioic acids include the sodium, lithium, potassium, magnesium and calcium salts thereof.

The term " β -acetyl-thiosulfate salt" refers is intended to include the sodium, lithium, potassium, magnesium and calcium salts thereof.

The term "pharmaceutically acceptable esters or salts" refers to esters or salts of Formula *I* derived from the combination of a compound of this invention and an organic or inorganic acid or base.

According to the present invention, ketals include diethers of lower alkanols, e.g. dimethyl and diethyl ketals, as well as cyclic ketals which include diethers of C₂₋₃ alkanediols, e.g. ethylene ketals and propylene ketals.

Examples of substituents which can be used in the compounds of Formula *I* are:

R is hydrogen, halogen, optionally substituted 1-alkynyl, lower alkoxy, alkyl, dialkylamino, or substituted alkyl;

R₁ is a substituted aralkynyl, arylalkyl, arylalkenyl, aryl, optionally substituted aralkylalkynyl, alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, optionally substituted heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;

R_2 is hydrogen, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, a keto group or amino group;

5 R_3 is an acetyl group, a ketal of an acetyl group; an alkoxyacetyl group, an alkylthioacetyl group, an alkylsulfinylacetyl group, an alkylsulfonylacetyl group, an aminoacetyl group, a trifluoroacetyl group; a hydroxyacetyl group; an alkoxyalkylacetyl group, e.g. a methoxymethylacetyl group or an ethoxymethyl-2'-methylene acetyl group; a hydroxyalkyl group, e.g. a hydroxymethyl group, a 1'-hydroxyethyl group, a 1'-hydroxypropyl group, or a 2'-hydroxy-2'-propyl group; a hydroxyacetyl dioic acid hemi-ester
10 salt, e.g. a succinyloxyacetyl group; an alkanoyloxyacetyl group, e.g. an acetoxyacetyl group; or a sulfoxyacetyl group; an alkylacetyl group, e.g. a methylacetyl group; a haloacetyl group; an ethynyl group; an optionally substituted heteroarylacetyl group; an optionally substituted heteroaralkylacetyl group which is also optionally substituted on the alkylene with a hydroxy,
15 alkoxy, alkanoyloxy or carbalkoxyl group; an optionally substituted heterocyclic-acetyl group; an acetyl thiosulfate salt; a cyano group; a alkylmethylene group (together with R_7); or an alkoxymethylene group (together with R_7);

20 R_4 is hydrogen or methyl,

R_5 is hydrogen;

R_6 is hydrogen, alkanoyl, aminocarbonyl, or alkoxycarbonyl;

R_7 is hydrogen, halogen, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, a methylene group (together with R_3), or an alkoxymethylene group (together with R_3);

25 R_8 is hydrogen or halogen;

R_9 is hydrogen, halogen, alkyl, alkoxy, arylalkoxy or amino; and

R_{10} is hydrogen, halogen, alkyl, haloalkyl, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, cyano, thiocyno or mercapto;

30 provided that when R_3 is an optionally substituted heteroarylacetyl group or acetylthiosulfate salts or when R is an optionally substituted 1-alkynyl group, then R_1 may further be hydrogen, alkyl, alkenyl, aryl, aralkyl, alkynyl,

optionally substituted aralkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocynoalkyl, or azidoalkyl.

A preferred group of compounds of Formula *I* are compounds where R is hydrogen or lower alkoxy. More preferred are compounds where R, R₅, R₆, R₇, R₈, R₉ and R₁₀ are hydrogen.

Another group of preferred compounds are compounds of Formula *I* where R₁ is substituted aralkynyl, e.g. R₁ is 4-substituted phenylalkynyl such as 4-acetylphenylethynyl, 4-methoxyphenylethynyl, 4-N,N-dimethylaminophenylethynyl, 4-cyanophenylethynyl, 4-carboxyphenylethynyl ethyl ester, 4-N,N-dialkylamidophenylethynyl, or where R₁ is oxoalkynyl, hydroxyalkynyl, acetoxyalkynyl, cyanoalkynyl, or alkoxyalkynyl.

An additional group of preferred compounds are wherein R₃ is acetyl, heteroarylacetyl, heterocyclic-acetyl, hydroxyalkyl, hydroxyacetyl, and their esters with physiologically acceptable acids. More preferably, R₃ is acetyl, β -succinyloxyacetyl, alkoxyacetyl, acetylthiosulfate salts, pyrazolylacetyl, or imidazolylacetyl.

An additional group of preferred compounds are wherein:

R is hydrogen, fluoro, chloro or lower alkoxy;

R₁ is substituted arylethynyl;

R₂ is hydrogen, a keto group or a dimethylamino group;

R₃ is a β -acetyl group, a dimethyl ketal of a β -acetyl group, a trifluoroacetyl group, a β -(hydroxyacetyl) group, a β -methoxymethylacetyl group, a β -(ethoxy)methyl-2'-methylene acetyl group, a β -(1'-hydroxyethyl) group, a β -(1'-hydroxypropyl) group, a β -(2'-hydroxy-2'propyl) group, a β -succinyloxyacetyl group, a β -hydroxyacetyl sodium succinate group, a β -acetoxyacetyl group, a β -sulfoxyacetyl group, a β -methylacetyl group, a β -chloroacetyl group, or a β -ethynyl group;

R₄ is hydrogen or methyl;

R₅, R₆, R₇, R₈, R₉ and R₁₀ are hydrogen;

the dotted lines all represent single bonds; and

R_7 is hydrogen or, when R_3 is β -hydroxyacetyl, R_7 is hydrogen or hydroxy.

Further preferred compounds are compounds of Formula I which are esters of hydroxyl groups at positions 3, 20 and/or 21. Preferred esters are those obtained from their corresponding acids and dioic acids: acetic, propionic, maleic, fumaric, ascorbic, pimelic, succinic, glutaric, bismethylene-salicylic, methanesulfonic, ethane-di-sulfonic, oxalic, tartaric, salicylic, citric, gluconic, itaconic, glycolic, *p*-aminobenzoic, aspartic, glutamic, gamma-amino-butyric, α -(2-hydroxyethylamino)propionic, glycine and other α -amino acids, phosphoric, sulfuric, glucuronic, and 1-methyl-1,4-dihyronicotinic.

Preferred are the following compounds: 3α -hydroxy- 3β -phenylethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -phenylethynyl- 5α -pregnan-20-one, 3α -hydroxy- 3β -(3',4'-dimethoxyphenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-methylphenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(2'-methoxyphenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-carboxyphenyl)ethynyl- 5β -pregnan-20-one ethyl ester, 3α -hydroxy- 3β -(4'-acetoxycetylphenyl)ethynyl- 5β -pregnan-20-one, 3β -(4'-acetylphenyl)ethynyl- 3α -hydroxy- 5α -pregnan-20-one, 3β -(4'-acetylphenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-dimethylaminophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-biphenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-nitrophenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-methoxyphenyl)ethynyl- 5β -pregnan-20-one, 3β -(4'-trifluoromethylphenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-chlorophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-cyanophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'(R/S)-hydroxypentynyl)- 3α -hydroxy- 5β -pregnan-20-one, 3α -hydroxy- 3β -phenyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -benzyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(2'-phenylethyl)- 5β -pregnan-20-one, 3α -hydroxy- 3β -[2-(3',4'-dimethoxyphenyl)ethyl]- 5β -pregnan-20-one, 3α -hydroxy- 3β -[6'-oxo-1'-heptynyl]- 5β -pregnan-20-one, 3α -hydroxy- 3β -(7'-oxo-1'-octynyl)- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-oxo-1'-pentynyl)- 5β -pregnan-20-one, 3β -[5'-(R/S)-

hydroxyhexynyl]-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-hydroxybutynyl)-3 α -
 hydroxy-5 β -pregnan-20-one, 3 β -(4'-hydroxybutynyl)-3 α -hydroxy-5 α -pregnan-
 20-one, 3 α -hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -
 methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one, 3 β -(4'-
 5 acetoxypheylethynyl)-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-
 acetylphenylethynyl)-3 α -hydroxy-19-nor-5 β -pregnan-20-one, 3 β -(4'-
 carboxypheylethynyl)-3 α -hydroxy-19-nor-5 β -pregnan-20-one ethylester, 3 β -
 (4'-carboxypheylethynyl)-3 α -hydroxy-5 α -pregnan-20-one ethylester, 3 β -[4'-
 (N,N-diethylcarboxamido)phenyl]ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 α -
 10 hydroxy-3 β -[5-oxo-1-hexynyl]-5 β -pregnan-20-one, 3 α -hydroxy-3 β -[5'-oxo-1'-
 hexynyl]-5 β -pregnan-20-one cyclic 5'-(1,2-ethanediyl acetal), 3 β -(5-cyano-1-
 pentynyl)-3 α -hydroxy-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(2-pyridyl)ethynyl-
 5 β -pregnan-20-one, 3 β -(6-hydroxy-1-hexynyl)-3 α -hydroxy-5 β -pregnan-20-
 one, 3 β -(6'-hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one 6'-
 15 hemisuccinate sodium salt, 3 β -(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -
 pregnan-20-one, 3 β -(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one
 5'-hemisuccinate sodium salt, 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -
 pregnan-20-one 4'-hemisuccinate sodium salt, 3 β -(4'-cyano-1'-butynyl)-3 α -
 hydroxy-5 β -pregnan-20-one, 3 β -(5'-acetoxyl-1'-pentynyl)-3 α -hydroxy-5 β -
 20 pregnan-20-one, 3 β -(4'-acetoxyl-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-
 one, 3 β -(4'-acetoxyl-1'-butynyl)-3 α -hydroxy-5 α -pregnan-20-one, 3 β -(6'-
 acetoxyl-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one, 3 α -hydroxy-3 β -[3-(2'-
 propynyloxy)-1-propynyl]-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(3-methoxy-1-
 propynyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(3-methoxy-1-propynyl)-5 α -
 25 pregnan-20-one, 3 α -hydroxy-3 β -[3-(4'-pyridinyloxy)-1-propynyl]-5 β -pregnan-
 20-one, 3 α -hydroxy-3 β -[3-(1'H-1,2,3-triazol-1'-yl)-1-propynyl]-5 β -pregnan-20-
 one, 3 α -hydroxy-3 β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]-5 β -pregnan-20-
 one, 3 α -hydroxy-3 β -(2'-thienyl)ethynyl-5 β -pregnan-20-one, 3 α -hydroxy-3 β -
 (3'-phenyl-1'-propynyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(3'-phenylpropyl)-
 30 5 β -pregnan-20-one, 3 α -hydroxy-3 β -[3-(1'H-pyrazol-1'-yl)-1-propynyl]-5 β -
 pregnan-20-one, 3 β -(3'-acetylphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-

one, 3 β -(3'-acetoxy-3'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -19-nor-pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-2-yl)-5 β -19-norpregnan-20-one, 3 α -hydroxy-21-(1-imidazolyl)-5 α -pregnan-20-one, sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl) thiosulfate, sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl) thiosulfate, sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl) thiosulfate, sodium S-(3 α -hydroxy-3 β -trifluoromethyl-5 β -pregnan-20-on-21-yl) thiosulfate, sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-5 β -pregnan-20-on-21-yl]thiosulfate, sodium S-(3 α -hydroxy-5 α -pregnan-20-on-21-yl) thiosulfate, and 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one, 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one, 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate sodium salt, and 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate sodium salt.

The more preferred neuroactive steroids include 3 β -(4'-acetylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one, 3 β -(4'-carboxylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one ethyl ester, 3 β -(4'-acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-carboxylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one ethyl ester, 3 β -(4'-acetylphenyl)ethynyl-3 α -hydroxy-5 β -19-norpregnan-20-one, 3 β -(4'-carboxylphenyl)ethynyl-3 α -hydroxy-5 β -19-norpregnan-20-one ethylester, 3 β -(4'-dimethylaminophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-biphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(4'-methoxyphenyl)ethynyl-5 β -pregnan-20-one, 3 β -(4'-trifluoromethylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-chlorophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -[4'(R/S)-hydroxypentynyl]-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-hydroxybutynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-hydroxybutynyl)-3 α -hydroxy-5 α -pregnan-20-one; 3 α -hydroxy-3 β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]-5 β -pregnan-20-one; 3 α -hydroxy-21-(1-imidazolyl)-5 β -pregnan-20-one, 3 β -(4'-

acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one, 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one, 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate sodium salt, and 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate sodium salt.

The especially preferred neuroactive steroids include 3 β -(4'-acetylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one, 3 β -(4'-acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-carboxylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one ethyl ester, 3 β -(4'-carboxylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one ethyl ester, 3 β -(4'-dimethylaminophenyl)ethynyl-5 β -pregnan-20-one, 3 β -(4'-biphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-hydroxybutynyl)-3 α -hydroxy-5 β -pregnan-20-one, 3 β -(4'-hydroxybutynyl)-3 α -hydroxy-5 α -pregnan-20-one; 3 α -hydroxy-3 β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]-5 β -pregnan-20-one; 3 α -hydroxy-21-(1-imidazolyl)-5 β -pregnan-20-one, 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one, 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one, 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate sodium salt, 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate sodium salt and 3 β -[4'(R/S)-hydroxypentynyl]-3 α -hydroxy-5 β -pregnan-20-one.

Synthetic Methods

The compounds according to the invention may be prepared by any convenient method, e.g. using conventional techniques such as are described in "Steroid Reactions," Djerassi, published in 1963 by Holden-Day, Inc., San Francisco or "Organic Reactions in Steroid Chemistry", Fried and Edwards, published in 1972 by Van Nostrand-Reinhold Co., New York.

General Methods

20-hydroxy pregnanes were prepared by the reduction of 20-keto pregnanes with conventional reducing agents.

21-Hemisuccinates were prepared from pregnan-20-one derivatives which were first brominated with molecular bromine to obtain the corresponding 21-bromo pregnanes. The bromo compounds were then reacted with various dioic acids, such as succinic acid, in the presence of an amine to yield 21-hydroxy esters. The resulting esters from the dioic acids were then converted to their sodium salts by conventional means.

21-Oxygenated compounds of this type may be prepared by a reaction sequence in which a pregnan-20-one is oxidized with lead tetraacetate to give a 21-acetoxy derivative, hydrolysis of the acetate to give a 21-alcohol, and acylation with an appropriate carboxylic acid derivative, for example, an anhydride or acid chloride or other reagent capable of replacing the hydrogen of the hydroxyl group, such as methanesulfonyl chloride.

Pregn-17-enes may be formed by the reaction of a 17-ketosteroid with a Wittig reagent such as the ylide derived from treatment of a *n*-propyltriphenylphosphonium bromide with a strong base such as potassium *t*-butoxide.

Example 1

3 α -Hydroxy-3 β -(2'-phenylethyl)-5 β -pregnan-20-one

A solution of 3 α -hydroxy-3 β -phenylethynyl-5 β -pregnan-20-one (44 mg) was dissolved in EtOAc (12 mL), Pd/C (5%, 12 mg) was added and the mixture was hydrogenated at 400 Kpa pressure overnight at rt. Filtration of the catalyst followed by evaporation of the solvent yielded the crude product, which was purified by chromatography over silica gel to isolate the pure title compound (33 mg); mp 153-154°C; TLC R_f (hexane:acetone 7:3) = 0.4.

Example 2

3 α -(3',4'-Dimethoxyphenylethynyl)-3 β -hydroxy-5 β -pregnan-20-one and 3 β -(3',4'-Dimethoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one

5 A solution of 2,2-dibromo-1-(3',4'-dimethoxyphenyl)ethene (prepared by the Wittig reaction of 3,4-dimethoxybenzaldehyde with carbon tetrabromide in the presence of triphenyl phosphine) (966 mg, 3 mmol) in dry THF (15 mL) was treated under N₂ with n-BuLi (2.5M in THF, 6 mmol, 2.4 mL) at -78°C. The mixture was stirred at this temperature for 2 hours and a solution of 5 β -pregnan-3,20-dione cyclic 20-(1,2-ethanediyl acetal) (720 mg, 2 mmol) 10 in dry THF (10 mL) was added dropwise over a period of 30 min. After stirring the resulting mixture at -78°C for 2 hr, the cooling bath was removed and the stirring was continued at rt for another hr. It was then quenched with 2N HCl solution (1 mL) at -10°C. The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (10 mL) the 15 solution was stirred at rt for 2 hr. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (1.2 g). This crude product was then 20 dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with the toluene:acetone mixture (96:4) gave a phenylacetylene compound, which was not characterized. Further elution with the same solvent yielded 3 α -(3',4'-dimethoxyphenylethynyl)-3 β -hydroxy-5 β -pregnan-20-one (120 mg) as a first fraction, and 3 β -(3',4'-dimethoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one as a second fraction (430 mg); mp 82-88°C. 25

An analogous method was used to prepare: 3 β -(4'-methoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-chlorophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(2'-methoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-

-21-

biphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-dimethylaminophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; and 3 β -(4'-cyanophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one.

Example 3

5 3 β -(3',4'-Dimethoxyphenylethyl)-3 α -hydroxy-5 β -pregnan-20-one

A mixture of Pd/C (5%, 28 mg) and EtOAc (12 mL) was presaturated with hydrogen by stirring it under hydrogen for 10 min. A solution of 3 β -(3',4'-dimethoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one (185 mg) in EtOAc (5 mL) was then added and the mixture was hydrogenated at 300 Kpa
10 pressure overnight at rt. Filtration of the catalyst followed by evaporation of the solvent yielded the crude product, which was purified by chromatography over silica gel (hexane:acetone 4:1) to isolate the pure title compound (135 mg); TLC R_f (hexane:acetone 4:1) = 0.14.

Example 4

15 3 β -(4'-Nitrophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of 2,2-dibromo-1-(4-nitrophenyl)ethene (prepared by the Wittig reaction of 4-nitrobenzaldehyde with carbon tetrabromide in the presence of triphenyl phosphine) (296 mg, 1 mmol) in dry THF (20 mL) was treated under N₂ with n-BuLi (2.5M in THF, 2 mmol, 0.8 mL) at -95°C. The
20 mixture was stirred at -80 to -100°C for 0.5 hr and then a solution of 5 β -pregnan-3,20-dione cyclic 20-(1,2-ethanediyl acetal) (120 mg, 0.5 mmol) in dry THF (10 mL) was added dropwise over a period of 10 min. After stirring the resulting mixture at -80°C for 1 hr, and then at 0°C for 1 more hr it was quenched with NH₄Cl solution (3 mL). The solvent was removed and the
25 residue was then dissolved in acetone (25 mL). After adding 2N HCl (10 mL)

-22-

the solution was stirred at rt for 1 hr. Saturated NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with CH₂Cl₂. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (400 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (96:4) gave the title compound as a brown solid (70 mg); TLC R_f (toluene:acetone 95:5) = 0.18.

Example 5

3β-Hydroxy-3α-phenyl-5β-pregnan-20-one and 3α-hydroxy-3β-phenyl-5β-pregnan-20-one

A solution of 5β-pregnan-3,20-dione cyclic 20-(1,2-ethanediyl acetal) (720 mg, 2 mmol) in 15 ml of dry THF was treated with phenyl magnesium bromide (3M in THF, 6 mmol, 2 mL) at -70°C. After stirring the mixture at this temperature for 3 hr and then at rt for 2 hr, it was quenched with 2N HCl (1 mL). The solvent was removed and the residue was dissolved in acetone (20 mL). After adding 1N HCl (5 mL) the solution was stirred at rt for 15 hr. The solvents were removed and the residue was extracted with CH₂Cl₂. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (1.3 g). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave a 3α-phenyl-3β-hydroxy-5β-pregnan-20-one (420 mg) as a first fraction. Further elution with the same solvent mixture yielded 3β-phenyl-3α-hydroxy-5β-pregnan-20-one (185 mg), m.p. 182-184°C.

Example 6

3 β -Hydroxy-3 α -benzyl-5 β -pregnan-20-one and 3 α -hydroxy-3 β -benzyl-5 β -pregnan-20-one

A solution of benzyl magnesium bromide (2M in THF, 2 mmol, 1 mL) was diluted with THF (15 mL) and was treated dropwise with a solution of 5 β -pregnan-3,20-dione cyclic 20-(1,2-ethanediyl acetal) (360 mg, 1 mmol) in dry THF (15 mL) at -60°C. After stirring the mixture at this temperature for 1 hr and then at rt for 15 hr, it was quenched with 2N HCl (1 mL). The solvent was removed and the residue was dissolved in acetone (20 mL). After adding 1N HCl (5 mL) the solution was stirred at rt for 30 min. It was neutralized with 2N NaOH. The precipitated solid was collected by filtration, washed with water and dried to yield 3 β -hydroxy-3 α -benzyl-5 β -pregnan-20-one (238 mg). The filtrate was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to give the crude product (160 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave 3 β -hydroxy-3 α -benzyl-5 β -pregnan-20-one (40 mg) as a first fraction. Further elution with the same solvent mixture yielded 3 α -hydroxy-3 β -benzyl-5 β -pregnan-20-one (30 mg), which was crystallized from hexane:CH₂Cl₂ (4:1) as colorless rods (15 mg); m.p. 133-141°C; TLC R_f (toluene:acetone 9:1) = 0.5.

Example 7

3 β -[3' (R/S)-Hydroxybutynyl]-3 α -hydroxy-5 β -pregnan-20-one

A solution of 3 (R/S)-hydroxybutyne (0.470 mL, 6 mmol) in dry THF (15 mL) was treated with n-BuLi (2.5M in THF, 12 mmol, 4.8 mL) at -70°C.

-24-

After stirring the mixture at this temperature for 0.5 hr, a solution of 5 β -pregnan-3,20-dione cyclic 20-(1,2-ethanediyl acetal) (1.08 g, 3 mmol) in dry THF (30 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was stirred at rt for another 1.5 hr. It was then quenched with NH₄Cl solution (3 mL). The solvent was removed and the residue was dissolved in acetone (10 mL). After adding 2N HCl (5 mL), the solution was stirred at rt for 1 hr. Saturated NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (1.4 g). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (85:15) gave 3 β -[3'(RS)-hydroxybutynyl]-3 α -hydroxy-5 β -pregnan-20-one (145 mg) as a colorless solid; TLC R_f (toluene:acetone 4:1) = 0.24.

An analogous method was used to prepare: 3 β -[4'(R/S)-hydroxypentynyl]-3 α -hydroxy-5 β -pregnan-20-one.

Example 8

3 β -(4'-Acetylphenylethynyl)-3 α -hydroxy-5 α -pregnan-20-one

A solution of 4-iodoacetophenone (95 mg, 0.39 mmol), 3 β -ethynyl-3 α -hydroxy-5 α -pregnan-20-one (106 mg, 0.3 mmol) in dry degassed pyrrolidine (3 mL) was stirred under argon at rt. Bis(triphenylphosphine)palladium(II) dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at rt for 15 hr. The TLC showed 100% conversion of the starting material, hence, the mixture was quenched with NH₄Cl solution (15 mL) and was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (150 mg). This

-25-

crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with hexane:acetone mixture (4:1) afforded 3 β -(4'-acetylphenylethynyl)-3 α -hydroxy-5 α -pregnan-20-one (35 mg) as a colorless solid; TLC R_f (hexane:acetone 7:3) = 0.4.

5 An analogous method was used to prepare: 3 α -hydroxy-3 β -(4'-trifluoromethylphenylethynyl)-5 β -pregnan-20-one; 3 β -(4'-acetylphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(4'-methylphenylethynyl)-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(4'-acetoxycetylphenylethynyl)-5 β -pregnan-20-one; 3 β -(3'-hydroxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(2',
10 4'-difluorophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(pentafluorophenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one; and 3 α -hydroxy-3 β -(4'-carboxyphenylethynyl)-5 β -pregnan-20-one ethyl ester.

Example 9

3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one

15 *3 α -Hydroxy-21-bromo-5 β -pregnan-20-one:* To a flask containing a solution of 3 α -hydroxy-5 β -pregnan-20-one (5.15 g, 16.5 mmol) in methanol (100 mL) was added a solution of bromine (1.1 mL) in methanol (30 mL) dropwise in such a rate to maintain the brown color of the bromine until this color was persistent. Then water (200 mL) was added and the mixture was extracted
20 with CH_2Cl_2 (3x100mL). The combined extracts were dried over Na_2SO_4 . Removal of the solvent resulted in the product as a foamy white solid (6.63 g). Other 21-bromo-pregnan-20-ones (3 β -ethynyl-3 α -hydroxy-21-bromo-5 β -pregnan-20-one, 3 β -methyl-3 α -hydroxy-21-bromo-5 α -pregnan-20-one and 3 α -hydroxy-3 β -trifluoromethyl-12-bromo-5 β -19-norpregnan-20-one) were
25 synthesized using the same method.

3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one: A mixture of 3 α -hydroxy-21-bromo-5 β -pregnan-20-one (0.86 g) and imidazole (0.37 g) in CH_3CN (12

-26-

mL) was heated under Ar to reflux for 1 h and cooled to 25°C. It was then poured into a separatory funnel containing NH₄Cl solution (100 mL, aq. sat.) and the product was extracted with EtOAc (3x50 mL). The combined organics were dried over Na₂SO₄ and the solvent was removed in vacuo. The pure product (0.59 g, 42%) was isolated by flash column chromatography.

The compounds 3 α -hydroxy-21-(1'-benzimidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(4-methyl-5-carbethoxyl)imidazol-1-yl]-5 β -pregnan-20-one ethylester, 3 α -hydroxy-21-(1'-imidazolyl)-5 α -pregnan-20-one, 3 β -ethynyl-3 α -hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1H-3,5-dimethylpyrazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'-imidazolyl)-3 β -methyl-5 α -pregnan-20-one, 3 α -hydroxy-21-(1'-pyrazolyl)-5 α -pregnan-20-one, 3 β -ethynyl-3 α -hydroxy-21-(1'-pyrazolyl)-5 β -pregnan-20-one, 21-(1'-benzimidazolyl)-3 α -hydroxy-3 β -methyl-5 α -pregnan-20-one, 3 α -hydroxy-21-(1'-pyrazolyl)-3 β -methyl-5 α -pregnan-20-one, 3 α -hydroxy-21-(pyrazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(2-methyl)imidazol-1-yl]-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(2'-formyl)imidazol-1-yl]-5 β -pregnan-20-one, 3 α -hydroxy-21-(1H-imidazol-1-yl)-3 β -trifluoromethyl-5 β -19-norpregnan-20-one, and 3 α -hydroxy-21-(pyrazol-1-yl)-3 β -trifluoromethyl-5 β -19-norpregnan-20-one were synthesized according to Example 9.

Example 10

3 α -Hydroxy-3 β -methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one:

To a solution of 1,2,4-triazole (146 mg) in THF (15 mL) under Ar was added NaH (56 mg) and the mixture obtained was stirred at 25°C for 20 min. Then a solution 3 β -methyl-3 α -hydroxy-21-bromo-5 α -pregnan-20-one (300 mg) in THF was added and the mixture thus obtained was stirred for 5 hr. It was then poured into a separatory funnel containing water (40 mL) and the product was extracted with CH₂Cl₂ (3x50 mL). The combined organics were dried

-27-

over Na₂SO₄ and the solvent was removed in vacuo. The pure product (187 mg, 64%) was isolated by flash column chromatography.

3 α -Hydroxy-21-(2'H-1,2,3,4-tetrazol-2'-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(9'H-purin-9'-yl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -methyl-21-(2'H-1',2',3'-triazol-2'-yl)-5 α -pregnan-20-one, 3 β -ethynyl-3 α -hydroxy-21-(1',2',4'-triazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -methyl-21-(1',2',3'-triazol-1'-yl)-5 α -pregnan-20-one, 3 α -hydroxy-21-(1',2',4'-triazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'H-1,2,3,4-tetrazol-1'-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(4-nitro)imidazol-1-yl]-5 β -pregnan-20-one, 3 α -hydroxy-21-(7'H-purin-7'-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(4',5'-dicyano)imidazol-1-yl]]-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'-1,2,4-triazol-1-yl)-3 β -trifluoromethyl-5 β -19-norpregnan-20-one, and 3 α -hydroxy-21-[1H-(4',5'-dichloro)imidazol-1-yl]]-5 β -pregnan-20-one, were synthesized according to the procedures set forth in Example 10.

Example 11

3 β -(4'-Acetoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one

a. 3 β -(4'-Hydroxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of 2,2-dibromo-1-(4-hydroxyphenyl)ethene (prepared by the Wittig reaction of 4-hydroxybenzaldehyde with carbon tetrabromide in the presence of triphenyl phosphine) (1.25 mg, 4.5 mmol) in dry THF (25 mL) was treated under N₂ with n-BuLi (2.5M in THF, 13.5 mmol, 5.4 mL) at -70°C. The mixture was then stirred at -70°C temp. for 0.5 hr, and a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (810 mg, 2.25 mmol) in dry THF (25 mL) was added dropwise over a period of 10 min. After stirring the resulting mixture at -78°C for 30 min, the cooling bath was removed and the stirring was continued at rt for another hr. It was then quenched with sat. NH₄Cl solution (4 mL) at -10°C. The solvent was removed

-28-

and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (6 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvent was removed under reduced pressure and the crude product (1.3 g) was used as such for the next step.

5 ***b. 3 β -(4'-Acetoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one***

The crude product from the above step was dissolved in CH₂Cl₂ (5 mL) and pyridine (3 mL). The resulting solution was added to a ice-cold mixture of acetyl chloride (3 mL) and pyridine (3 mL). The mixture was stirred at 0°C for 30 min. and was poured into ice (50 g). 2N HCl (10 mL) was added and
10 the mixture was diluted with more CH₂Cl₂. The organic layer was separated, washed with water, brine, and dried over anhyd. MgSO₄. Removal of solvent gave a crude solid (2 g) which was purified by column chromatography over silica gel. Elution with toluene:acetone mixture (95:5) gave 3 α -(4'-acetoxyphenylethynyl)-3 β -hydroxy-5 β -pregnan-20-one (150 mg). Further
15 elution with the same solvent mixture yielded 3 β -(4'-acetoxyphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one (530 mg); m.p. 171-176°C; TLC R_f (hexane:acetone 7:3) = 0.41.

Example 12

3 β -(4'-Acetylphenylethynyl)-3 α -hydroxy-19-nor-5 β -pregnan-20-one

20 A solution of 4-iodoacetophenone (60 mg, 0.24 mmol), 3 β -ethynyl-3 α -hydroxy-19-nor-5 β -pregnan-20-one (80 mg, 0.24 mmol) in dry degassed triethylamine (0.5 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)-palladium(II)dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH₂Cl₂ (4 mL)
25 was added and the mixture was stirred at 23°C for 3 hr. The TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with

-29-

hexane:acetone (4:1) gave 3β -(4'-acetylphenylethynyl)- 3α -hydroxy-19-nor- 5β -pregnan-20-one (30 mg) as a colorless solid; mp 65-67°C, TLC R_f (hexane:acetone 4:1) = 0.12.

Example 13

5 ***3β -(4'-Carboxyphenylethynyl)- 3α -hydroxy-19-nor- 5β -pregnan-20-one ethyl ester***

A solution of ethyl 4-iodobenzoate (70 mg, 0.24 mmol) and 3β -ethynyl- 3α -hydroxy-19-nor- 5β -pregnan-20-one (80 mg, 0.24 mmol) in dry degassed triethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)-
10 palladium(II)dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 1 hr. CH_2Cl_2 (4 mL) was added and the mixture was stirred at 23°C for 3 hr. The TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (4:1) gave 3β -
15 (4'-carboxyphenylethynyl)- 3α -hydroxy-19-nor- 5β -pregnan-20-one ethyl ester (22 mg) as a colorless solid; mp 164-166°C, TLC R_f (hexane:acetone 4:1) = 0.27.

Example 14

3β -(4'-Carboxyphenylethynyl)- 3α -hydroxy- 5α -pregnan-20-one ethyl ester

20 A solution of ethyl 4-iodobenzoate (83 mg, 0.3 mmol), 3β -ethynyl- 3α -hydroxy- 5α -pregnan-20-one (103 mg, 0.3 mmol) in dry degassed triethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)-palladium(II)dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 1 hr. CH_2Cl_2 (4 mL) was added and the mixture
25 was stirred at 23°C for 1.5 hr. The TLC showed 100% conversion of the

-30-

starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (4:1) gave 3 β -(4'-carboxyphenylethynyl)-3 α -hydroxy-5 α -pregnan-20-one ethyl ester (10 mg) as a colorless solid; mp 190-192°C, TLC R_f (hexane:acetone 4:1) = 0.27.

5

Example 15

3 β -[4'-(N,N-diethylcarboxamido)phenyl]ethynyl-3 α -hydroxy-5 β -pregnan-20-one

A solution of 4-(N,N-diethylcarboxamido)iodobenzene (91 mg, 0.3 mmol), 3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one (103 mg, 0.3 mmol) in dry degassed triethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)palladium(II)dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 1 hr. CH₂Cl₂ (4 mL) was added and the mixture was stirred at 23°C for 0.5 hr. The TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (3:1) gave 3 β -[4'-(N,N-diethylcarboxamido)phenyl]ethynyl-3 α -hydroxy-5 α -pregnan-20-one ethyl ester (18 mg) as a colorless solid; TLC R_f (hexane:acetone 3:1) = 0.22.

10

15

Example 16

20

3 α -Hydroxy-3 β -[5-oxo-1-hexynyl]-5 β -pregnan-20-one cyclic (1,2-ethanediyl acetal)

25

A solution of 1-hexyn-5-one cyclic (1,2-ethanediyl acetal) (493 mg, 3.52 mmol) in dry THF (15 mL) was treated with n-BuLi (2.5M in THF, 3 mmol, 1.2 mL) at -60°C. After stirring the mixture at -78°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (360 mg,

-31-

1 mmol) in THF (15 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (3 mL). The solvent was removed and the residue was then dissolved in acetone (40 mL). After adding 1N HCl (4 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO₃ soln., water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (700 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (93:7) gave 3 α -hydroxy-3 β -[5-oxo-1-hexynyl]-5 β -pregnan-20-one cyclic (1,2-ethanediyl acetal) (210 mg) as a colorless solid; mp 130-133°C; TLC R_f (toluene:acetone 9:1) = 0.33.

Example 17

3 α -Hydroxy-3 β -[5-oxo-1-hexynyl]-5 β -pregnan-20-one

3 α -Hydroxy-3 β -[5-oxo-1-hexynyl]-5 β -pregnan-20-one cyclic (1,2-ethanediyl acetal) (95 mg) was dissolved in acetone (5 mL). After adding 2N HCl (1 mL) the solution was stirred at rt for 3 hr. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude title product (100 mg), which was then crystallized from hexane-acetone as colorless rods, yield 63 mg; mp 104-106°C; TLC R_f (hexane:acetone 7:3) = 0.27.

An analogous method was used to prepare 3 α -hydroxy-3 β -[6-oxo-1-heptynyl]-5 β -pregnan-20-one, using 1-heptyn-6-one cyclic 6-(1,2-ethanediyl acetal).

Example 18

3 β -(5-Cyano-1-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of 5-cyanopentyne (0.84 mL, 8 mmol) in dry THF (20 mL) was treated with n-BuLi (2.5M in THF, 7.8 mmol, 3.2 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (720 mg, 2 mmol) in THF (20 mL) was added and the mixture was stirred at -78°C for 0.5 hr. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (3 mL). The solvent was removed and the residue was then dissolved in acetone (40 mL). After adding 1N HCl (4 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (1.55 g). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave 3 α -(5-cyano-1-pentynyl)-3 β -hydroxy-5 β -pregnan-20-one (170 mg) as a first fraction. Further elution with the same solvent mixture yielded 3 β -(5-cyano-1-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one (480 mg) as a colorless solid; mp 134-136°C; TLC R_f (hexane:acetone 7:3) = 0.3.

An analogous method was used to prepare 3 β -(4-cyano-1-butynyl)-3 α -hydroxy-5 β -pregnan-20-one.

Example 19

3 α -Hydroxy-3 β -(2-pyridyl)ethynyl-5 β -pregnan-20-one

A solution of 2-ethynylpyridine (270 mg, 2.6 mmol) in dry THF (15 mL) was treated with n-BuLi (2.5M in THF, 2.5 mmol, 1 mL) at -60°C.

-33-

After stirring the mixture at -78°C for 0.5 hr, a solution of 5β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (170 mg, 0.47 mmol) in THF (15 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH_4Cl solution (3 mL). The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 15 min. Sat. NaHCO_3 soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO_4 the solution was filtered and evaporated to yield the crude product (360 mg). This crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave the unreacted ethynylpyridine as a first fraction. Further elution with the same solvent mixture yielded 3β -(2-pyridyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one (107 mg) as a colorless solid; mp $192\text{--}195^{\circ}\text{C}$; TLC R_f (toluene:acetone 87:13) = 0.21.

Example 20

3β -(6-hydroxy-1-hexynyl)- 3α -hydroxy- 5β -pregnan-20-one

A solution of 5-hexyn-1-ol (1.35 mL, 12 mmol) in dry THF (15 mL) was treated with n-BuLi (9.6 mL, 2.5M in THF, 24 mmol) at -65°C . After stirring the mixture at -78°C for 0.5 hr, a solution of 5β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (1.08 g, 3 mmol) in THF (20 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the stirring was continued at rt for 45 min. The mixture was then quenched with NH_4Cl solution (5 mL). The solvent was removed the residue was extracted with EtOAc. The organic layer was washed with water, dil. NaHCO_3 soln., water, and brine. After drying over anhyd. MgSO_4 . The solution was filtered and evaporated to yield the crude product (1.90 g). This

crude product was then crystallized from EtOAc to yield the pure product as colorless rods (890 mg). This was then dissolved in acetone (120 mL). After adding 2N HCl (3 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄, the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave the unreacted hexynol as a first fraction. Further elution with the same solvent mixture yielded 3 α -(6-hydroxy-1-hexynyl)-3 β -hydroxy-5 β -pregnan-20-one (60 mg), and then 3 β -(6-hydroxy-1-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one (620 mg) as a colorless solid; mp 132-134°C; TLC R_f (hexane:acetone 7:3) = 0.23.

Example 21

15 3 β -(6'-Hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one 6'-hemisuccinate sodium salt

a. 3 β -(6'-Hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one 6'-hemisuccinate

20 A solution of 3 β -(6'-hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one (600 mg, 1.45 mmol) in pyridine (5 mL) was treated with succinic anhydride (600 mg, 6 mmol) and 4-(N,N-dimethyl)aminopyridine (20 mg). The mixture was heated to 70-75°C for 1.25 hr. The tlc showed 100% conversion. It was cooled to rt and was poured into ice-2N HCl. The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:acetone mixture (7:3) gave 3 β -(6'-hydroxy-1'-hexynyl)-

25

-35-

3 α -hydroxy-5 β -pregnan-20-one 6'-hemisuccinate (700 mg); TLC R_f (hexane:acetone:AcOH 70:30:0.5) = 0.21.

b. 3 β -(6'-hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one 6'-hemisuccinate sodium salt

5 A mixture of the above hemisuccinate (400 mg), NaHCO₃ (68 mg), water (8 mL), and CH₂Cl₂ (1 mL) was stirred at rt for 15 min. The solvent was removed and the residue was freeze-dried to yield the sodium salt as a colorless solid (400 mg).

Example 22

10 *3 β -(5'-Hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one*

A solution of 4-pentyn-1-ol (1.1 mL, 12 mmol) in dry THF (15 mL) was treated with n-BuLi (9.9 mL, 2.5M in THF, 24.5 mmol) at -65°C. After stirring the mixture at -78°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (1.08 g, 3 mmol) in THF (20 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the stirring was continued at rt for 45 min. The mixture was then quenched with NH₄Cl solution (5 mL). The solvent was removed the residue was then dissolved in acetone (30 mL). After adding 2N HCl (7 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone:EtOAc mixture (70:15:15) gave the unreacted pentynol as a first fraction. Further elution with the same solvent mixture yielded 3 α -(5'-hydroxy-1'-pentynyl)-3 β -hydroxy-5 β -pregnan-20-one (100 mg), and then 3 β -

15

20

25

-36-

(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one (650 mg) as a colorless solid; mp 160-163°C; TLC R_f (toluene:acetone:EtOAc 70:15:15) = 0.28.

An analogous method was used to prepare: 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -19-norpregnan-20-one; 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 α -pregnan-20-one; 3 β -[4'(R/S)-hydroxy-1'-pentynyl]-3 α -hydroxy-5 α -pregnan-20-one; 3 β -[3'(R/S)-hydroxy-1'-butynyl]-3 α -hydroxy-5 α -pregnan-20-one; and 3 β -(3'-hydroxy-1'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one.

Example 23

3 β -(5'-Hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate sodium salt

a. 3 β -(5'-Hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate

A solution of 3 β -(6'-hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one (350 mg, 0.87 mmol) in pyridine (3 mL) was treated with succinic anhydride (380 mg, 3.8 mmol) and 4-(N,N-dimethyl)aminopyridine (20 mg). The mixture was heated to 65-70°C for 1 hr. The TLC showed 100% conversion. It was cooled to rt and was poured into ice-2N HCl. The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (900 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:acetone mixture (7:3) gave 3 β -(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate (350 mg); TLC R_f (hexane:acetone:AcOH 70:30:0.5) = 0.25.

-37-

b. 3 β -(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate sodium salt

A mixture of the above hemisuccinate (345 mg), NaHCO₃ (60 mg), water (5 mL), THF (2 mL), and CH₂Cl₂ (1 mL) was stirred at rt for 1 hr. The solvent was removed and the residue was freeze-dried to yield the sodium salt as a colorless solid (340 mg).

An analogous method was used to prepare hemisuccinate sodium salts from: 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one; 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -19-norpregnan-20-one; 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 α -pregnan-20-one; 3 β -[4'(R/S)-hydroxy-1'-pentynyl]-3 α -hydroxy-5 α -pregnan-20-one; 3 β -[3'(R/S)-hydroxy-1'-butynyl]-3 α -hydroxy-5 α -pregnan-20-one; and 3 β -(3'-hydroxy-1'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one.

Example 24

3 β -(5'-Acetoxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of pyridine (280 mg) in CH₂Cl₂ (2 mL) was treated with acetyl chloride (280 mg) at 0-5°C. A solution of 3 β -(5'-hydroxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one (130 mg) in CH₂Cl₂ (3 mL) was added. The stirring was continued at 0°C for 20 min. The TLC showed 100% conversion, hence, the mixture was poured into ice-2N HCl (20g, 2 mL). The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (9:1) gave 3 β -(5'-acetoxy-1'-pentynyl)-3 α -hydroxy-5 β -pregnan-20-one (100 mg); mp 84-87°C; TLC R_f (hexane:acetone 70:30) = 0.38.

Example 25

3 β -(4'-Acetoxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of pyridine (280 mg) in CH₂Cl₂ (2 mL) was treated with acetyl chloride (280 mg) at 10°C. A solution of 3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one (110 mg) in CH₂Cl₂ (3 mL) was added. The stirring was continued at 10°C for 30 min. The TLC showed 100% conversion, hence, the mixture was poured into ice-2N HCl (20 g, 3 mL). The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:acetone mixture (4:1) gave 3 β -(4'-acetoxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one (92 mg); mp 170-173°C; TLC R_f (hexane:acetone 70:30) = 0.3.

Example 26

3 β -(6'-Acetoxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of pyridine (2 mL) in CH₂Cl₂ (10 mL) was treated with acetyl chloride (2 mL) at 0°C. A solution of 3 β -(6'-hydroxy-1'-hexynyl)-3 α -hydroxy-5 β -pregnan-20-one (400 mg, 0.96 mmol) in CH₂Cl₂ (5 mL) was added. The stirring was continued at 0°C for 20 min. The TLC showed 100% conversion, hence, the mixture was poured into ice-2N HCl (50 g, 11 mL). The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (500 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5)

-39-

gave 3β -(6'-acetoxy-1'-hexynyl)- 3α -hydroxy- 5β -pregnan-20-one (130 mg); mp 85-87°C; TLC R_f (toluene:acetone 93:7) = 0.2.

Example 27

3 α -Hydroxy-3 β -[3-(2'-propynyloxy)-1-propynyl]-5 β -pregnan-20-one

5 A solution of propargyl ether (0.3 mL, 3 mmol) in dry THF (10 mL) was treated with n-BuLi (2.4M in THF, 3 mmol, 1.25 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (360 mg, 1 mmol) in THF (10 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH_4Cl solution (5 mL). The solvent was removed and the residue was then dissolved in acetone (40 mL). After adding 1N HCl (4 mL) the solution was stirred at rt for 15 min. Sat. NaHCO_3 soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO_4 the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with toluene:acetone mixture (95:5) gave 3β -Hydroxy- 3α -[3-(2'-propynyloxy)-1-propynyl]- 5β -pregnan-20-one (31 mg) as a first fraction. Further elution with the same solvent mixture yielded 3α -hydroxy- 3β -[3-(2'-propynyloxy)-1-propynyl]- 5β -pregnan-20-one (255 mg) as a colorless solid; mp 103-106°C; TLC R_f (toluene:acetone 95:5) = 0.39.

10

15

20

Example 28

3 α -Hydroxy-3 β -(3-methoxy-1-propynyl)-5 β -pregnan-20-one

A solution of methyl propargyl ether (0.25 mL, 3 mmol) in dry THF (10 mL) was treated with n-BuLi (2.4M in THF, 2.9 mmol, 1.20 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (185 mg, 0.5 mmol) in THF (10 mL) was added and the mixture was stirred at -78°C for 20 min. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (2 mL). The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 15 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (250 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (93:7) gave 3 β -hydroxy-3 α -(3-methoxy-1-propynyl)-5 β -pregnan-20-one (19 mg) as a first fraction. Further elution with the same solvent mixture yielded 3 α -hydroxy-3 β -(3-methoxy-1-propynyl)-5 β -pregnan-20-one (115 mg) as a colorless solid; mp 155-159°C; TLC R_f (hexane:acetone 7:3) = 0.25.

Example 29

3 α -Hydroxy-3 β -[3-(4'-pyridinyloxy)-1-propynyl]-5 β -pregnan-20-one

A solution of propargyl 4-pyridyl ether (prepared according to (Thummel et al, *J. Org. Chem.* 1978, 43, 4882) (173 mg, 1.3 mmol) in dry THF (15 mL) was treated with n-BuLi (2.5M in THF, 1.3 mmol, 0.52 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5 β -

-41-

pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (180 mg, 0.5 mmol) in THF (15 mL) was added and the mixture was stirred at -78°C for 20 min. The cooling bath was removed and the stirring was continued at rt for 1 hr. The mixture was quenched with NH₄Cl solution (2 mL). The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 20 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (250 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with CH₂Cl₂:acetone mixture (90:10) gave 3 α -hydroxy-3 β -[3-(4'-pyridinyloxy)-1-propynyl]-5 β -pregnan-20-one (145 mg) as a colorless solid; mp 84-90°C; TLC R_f (CH₂Cl₂:acetone 85:15) = 0.17.

Example 30

3 α -Hydroxy-3 β -[3-(1'H-1,2,3-triazol-1'-yl)-1-propynyl]-5 β -pregnan-20-one

A solution of 1-(2-propynyl)-1H-1,2,3-triazole (prepared by the reaction of triazole with propargyl bromide) (77 mg, 0.72 mmol) in dry THF (10 mL) was treated with n-BuLi (2.5M in THF, 0.72 mmol, 0.28 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (130 mg, 0.36 mmol) in THF (10 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (1 mL). The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 30 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd.

MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (85:15) gave 3 α -hydroxy-3 β -[3-(1'H-1,2,3-triazol-1'-yl)-1-propynyl]-5 β -pregnan-20-one (56 mg) as a colorless solid; mp 142-144°C; TLC R_f (hexane:acetone 7:3) = 0.33.

Example 31

3 α -Hydroxy-3 β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]-5 β -pregnan-20-one

A solution of 2-(2-propynyl)-2H-1,2,3-triazole (prepared by the reaction of triazole with propargyl bromide) (35 mg, 0.33 mmol) in dry THF (10 mL) was treated with n-BuLi (2.5M in THF, 0.33 mmol, 0.15 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (60 mg, 0.16 mmol) in THF (10 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (1 mL). The solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 30 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (85:15) gave pregnan-3,20-dione (20 mg) as a first fraction. Further elution with the same solvent yielded 3 α -hydroxy-3 β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]-5 β -pregnan-20-one (20 mg) as a colorless solid; mp 139-140°C; TLC R_f (hexane:acetone 4:1) = 0.17.

Example 32

3 α -Hydroxy-3 β -(2'-thienyl)ethynyl-5 β -pregnan-20-one

A solution of 4-iodothiophene (63 mg, 0.3 mmol), 3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one (103 mg, 0.3 mmol) in dry degassed triethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)palladium(II) dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH₂Cl₂ (5 mL) was added and the mixture was stirred at 23°C for 1 hr. The TLC showed 100% conversion of the starting material, hence, the solvent was removed, and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (4:1) gave 3 α -hydroxy-3 β -(2'-thienyl)ethynyl-5 β -pregnan-20-one (50 mg) as a colorless solid; mp 205-206°C, TLC R_f (hexane:acetone 4:1) = 0.35.

An analogous method was used to prepare 3 α -hydroxy-3 β -(5'-acetyl-2'-thienyl)ethynyl-5 β -pregnan-20-one; mp 226-228°C, TLC R_f (hexane:acetone 4:1) = 0.14.

Example 33

3 α -Hydroxy-3 β -(3'-phenyl-1'-propynyl)-5 β -pregnan-20-one

A solution of 3-phenyl-1-propyne (0.25 mL, 2 mmol) in dry THF (17 mL) was treated with n-BuLi (2.5M in THF, 2 mmol, 0.8 mL) at -70°C. After stirring the mixture at -75°C for 10 min., a solution of 5 β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (206 mg, 0.6 mmol) in THF (10 mL) was added and the mixture was stirred at -78°C for 20 min. The cooling bath was removed and the mixture was quenched with NH₄Cl solution (5 mL). The solvent was removed and the residue was then dissolved in acetone (15 mL). After adding 2N HCl (4 mL) the solution was stirred at rt for 20 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed

and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO_4 the solution was filtered and evaporated to yield the crude product (460 mg). This crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with toluene:acetone mixture (85:15) gave the unreacted phenylpropyne as a first fraction. Further elution with the same solvent yielded 3α -hydroxy- 3β -(3'-phenyl-1'-propynyl)- 5β -pregnan-20-one (175 mg) as a colorless solid; mp 124-132°C; TLC R_f (hexane:acetone 7:3) = 0.46.

Example 34

3 α -Hydroxy-3 β -(3'-phenylpropyl)-5 β -pregnan-20-one

A solution of the above phenylpropynyl derivative (50 mg) in EtOAc (10 mL) was hydrogenated over Pd/C (10 mg, 5%) under 2 atm. of H_2 for 45 min. The mixture was then filtered through a small pad of Celite, and concentrated to yield the title compound as a colorless solid (40 mg); mp 41-46°C; R_f (hexane:acetone 7:3) = 0.48.

Example 35

3 α -Hydroxy-3 β -[3-(1'H-pyrazol-1'-yl)-1-propynyl]-5 β -pregnan-20-one

A solution of 1-(2-propynyl)-1H-pyrazole (prepared by the reaction of pyrazole with propargyl bromide) (160 mg, 1.5 mmol) in dry THF (15 mL) was treated with n-BuLi (2.5M in THF, 1.5 mmol, 0.6 mL) at -70°C. After stirring the mixture at -75°C for 0.5 hr, a solution of 5β -pregnan-3,20-dione, cyclic 20-(1,2-ethanediyl acetal) (180 mg, 0.5 mmol) in THF (15 mL) was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the mixture was quenched with NH_4Cl solution (1 mL). The

solvent was removed and the residue was then dissolved in acetone (25 mL). After adding 2N HCl (2 mL) the solution was stirred at rt for 30 min. Sat. NaHCO₃ soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (9:1) gave 3 α -hydroxy-3 β -[3-(1'H-pyrazol-1'-yl)-1-propynyl]-5 β -pregnan-20-one (80 mg) as a colorless solid; mp 113-115°C; TLC R_f (toluene:acetone 9:1) = 0.19.

Example 36

3 β -(3'-Acetylphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of 3-iodoacetophenone (74 mg, 0.3 mmol), 3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one (103 mg, 0.3 mmol) in dry degassed triethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)palladium(II) dichloride (5 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH₂Cl₂ (5 mL) was added and the mixture was stirred at 23°C for 1.5 hr. The TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (85:15) gave 3 β -(3'-acetylphenylethynyl)-3 α -hydroxy-5 β -pregnan-20-one (30 mg) as a colorless solid; mp °C, TLC R_f (hexane:acetone 4:1) = 0.

Example 37

3 β -(3'-Acetoxy-3'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one

A solution of pyridine (280 mg) in CH₂Cl₂ (2 mL) was treated with acetyl chloride (280 mg) at 0-5°C. A solution of 3 β -(3'-hydroxy-1'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one (130 mg) in CH₂Cl₂ (3 mL) was added. The stirring was continued at 0°C for 30 min. The TLC showed 100% conversion, hence, the mixture was poured into ice-2N HCl (20g, 3 mL). The organics were extracted with EtOAc. The organic layer was washed with 0.2N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (150 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with toluene:acetone mixture (4:1) gave 3 β -(3'-acetoxy-1'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one (110 mg); mp 132-150°C; TLC R_f (hexane:acetone 70:30) = 0.37.

Example 38

3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -pregnan-20-one

a. 21-Bromo-3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-5 β -pregnan-20-one

A solution of 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-5 β -pregnan-20-one (386 mg, 1 mmol) in MeOH (20 mL) was treated with two drops of acetyl chloride, followed by bromine (1.2 mmol). The mixture was stirred at rt for 2.5 hr and was poured into ice-water. The separated solid was collected by filtration, washed with water, dried (410 mg). This semi-dried solid was then dissolved in EtOAc and dried over anhyd. MgSO₄. Filtration and removal of the solvent gave the crude bromo derivative, and it was used as such for the next step.

-47-

b. *3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -pregnan-20-one*

A suspension of NaH (138 mg, 95 %, 5.46 mmol) in THF (10 mL) was treated with a solution of imidazole (345 mg, 5.1 mmol) in THF (10 mL) at rt. After stirring the mixture for 30 min a solution of the crude bromo derivative (95 mg, 0.2 mmol) in THF (10 mL) was added. The stirring was continued at rt for 1 hr. Sat. NH₄Cl soln. was added and the solvent was removed. The residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (100 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with CH₂Cl₂:MeOH:NEt₃ (95:4.5:0.5) mixture gave 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -pregnan-20-one (40 mg) as a colorless solid; mp 117-119°C; TLC R_f (CH₂Cl₂:MeOH:NEt₃ 95:4.5:0.5) 0.21.

Similarly prepared were 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,4-triazol-1-yl)-5 β -pregnan-20-one; mp 208-210°C; TLC R_f (CH₂Cl₂:MeOH:NEt₃ 95:4.5:0.5) 0.24; 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(tetrazol-1-yl)-5 β -pregnan-20-one; mp 110-112°C; TLC R_f (CH₂Cl₂:MeOH:NEt₃ 96:3.5:0.5) 0.11; 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-1-yl)-5 β -pregnan-20-one; mp 101-104°C; TLC R_f (CH₂Cl₂:MeOH:NEt₃ 95:4.5:0.5) 0.2.

Example 39

3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -19-norpregnan-20-one

a. *21-Bromo-3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-5 β -19-norpregnan-20-one*

A solution of 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-5 β -19-norpregnan-20-one (710 mg, 1.9 mmol) in MeOH (60 mL) was heated to 33°C and was

5 treated with two drops of acetyl chloride, followed by bromine (2.28 mmol, 0.116 mL). The mixture was stirred at rt for 1.5 hr and was poured into ice-water. The separated solid was collected by filtration, washed with water, dried. This semi-dried solid was then dissolved in EtOAc and dried over anhyd. MgSO₄. Filtration and removal of the solvent gave the crude bromo derivative (870 mg), and it was used as such for the next step.

b. 3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -19-norpregnan-20-one

10 A suspension of NaH (138 mg, 95%, 5.46 mmol) in THF (10 mL) was treated with a solution of imidazole (345 mg, 5.1 mmol) in THF (10 mL) at rt. After stirring the mixture for 30 min a solution of the crude bromo derivative (90 mg, 0.2 mmol) in THF (10 mL) was added. The stirring was continued at rt for 1 hr. Sat. NH₄Cl soln. was added and the solvent was removed. The residue was extracted with EtOAc. The organic layer was
15 washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (100 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with CH₂Cl₂:MeOH:NEt₃ (95:4.5:0.5) mixture gave
20 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)-5 β -19-norpregnan-20-one (25 mg) as a colorless solid; mp 118-127°C; TLC R_f (CH₂Cl₂:MeOH:NEt₃ 95:4.5:0.5) 0.28.

Example 40

25 *3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-2-yl)-5 β -19-norpregnan-20-one and 3 α -Hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-1-yl)-5 β -19-norpregnan-20-one*

A suspension of NaH (11 mg, 95%, 0.44 mmol) in THF (10 mL) was treated with a solution of 1,2,3-triazole (30 mg, 0.44 mmol) in THF (10 mL) at rt. After stirring the mixture for 30 min a solution of the crude 21-bromo-3 α -

hydroxy-3 β -(4-hydroxybutyn-1-yl)-5 β -pregnan-20-one (100 mg, 0.22 mmol) in THF (10 mL) was added. The stirring was continued at rt for 1 hr. Sat. NH₄Cl soln. was added and the solvent was removed. The residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄, the solution was filtered and evaporated to yield the crude product (100 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with CH₂Cl₂:acetone (4:1) mixture gave 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(2H-1,2,3-triazol-2-yl)-5 β -19-norpregnan-20-one (15 mg) as a first fraction; mp 158-160°C; TLC R_f (CH₂Cl₂:acetone 4:1) 0.36. Further elution with the same solvent mixture yielded 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1H-1,2,3-triazol-1-yl)-5 β -19-norpregnan-20-one (15 mg); mp 188-190°C; TLC R_f (CH₂Cl₂:acetone 4:1) 0.2.

Example 41

3 α -Hydroxy-2 β -morpholinyl-21-[1'-(1',2',4'-triazolyl)]-5 α -pregnan-20-one

To a solution of 1,2,4-triazole (108 mg, 1.57 mmol) in dry THF (2.5 ml) was added sodium hydride (36 mg, 1.50 mmol). The mixture was stirred at 25°C under argon for 0.5 hour. Then 3 α -hydroxy-2 β -morpholinyl-21-bromo-5 α -pregnan-20-one (130 mg, 0.27 mmol) was added and the mixture was further stirred at 25°C under argon for 2.5 hours. Water (20 ml) was added slowly to the reaction mixture. The product was extracted with ethyl acetate (3 x 25 ml). The combined extracts were washed with brine (20 ml) and water (3 x 20 ml). The organic solution obtained was dried over sodium sulfate and the solvent was removed in vacuo to give the crude product (130 mg). The pure product (90 mg, 71%) was obtained by flash chromatography (30 g of silica gel and 300 ml of mixed solvent of CH₂Cl₂ : MeOH : Et₃N = 95 : 4.5 : 0.5, R_f = 0.14).

Example 42

3 α -Hydroxy-21-(1'-uracil)-5 α -pregnan-20-one

To a suspension of uracil (112 mg, 1 mmol) and K₂CO₃ (138 mg, 1 mmol) in DMF (1.5 mL) was added 3 α -hydroxy-21-bromo-5 α -pregnan-20-one (400 mg, 1 mmol) and the mixture obtained was stirred at 25°C for 65 h. It was then poured into a separatory funnel containing water (60 ml) and ethyl acetate (100 mL). The water layer was removed after shaking and the white solid in the organic layer was obtained by filtration as the product (87 mg, 20%). m.p.: 262-265°C (decomp).

Example 43

Sodium S-(3 α -hydroxy-5 α -pregnan-20-on-21-yl) thiosulfate

To a solution of 21-bromo-3 α -hydroxy-5 α -pregnan-20-one (500 mg, 1.26 mmol) dissolved in 50 mL of ethanol was added dropwise a solution of sodium thiosulfate (199 mg, 1.26 mmol) in 10 mL of water. The reaction was allowed to stir at rt until TLC (1:1 acetone/dichloromethane) indicated complete consumption of the starting bromide. Concentration of the reaction in vacuo gave the desired thiosulfate contaminated with sodium bromide. Flash column chromatography (silica gel eluted with a gradient from 1:1 to 3:1 acetone/dichloromethane) afforded 430 mg (75 %) of the title compound as a white solid.

Similarly prepared were sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl) thiosulfate, purified by flash chromatography as above, sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl) thiosulfate, purified by recrystallization from 50:1 methanol/water, sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl) thiosulfate, purified by flash chromatography with silica gel and 3:1 acetone/ethanol, sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-

-51-

5 β -pregnan-20-on-21-yl] thiosulfate, purified by trituration with hot acetone, and sodium S-(3 α -hydroxy-3 β -trifluoromethyl-5 β -19-norpregnan-20-on-21-yl) thiosulfate, purified by trituration with hot acetone/chloroform.

Example 44

5 3 α -Hydroxy-3 β -(E)-(2-phenylethenyl)-5 α -pregnan-20-one.

Benzyl phenyl sulfoxide

To a solution of benzyl phenyl sulfide (Aldrich; 1.068 g, 5.33 mmol) in 25 mL of CH₂Cl₂ at -78°C was slowly added a solution of *m*-chloroperbenzoic acid (Aldrich, 50-60%; 760 mg, 2.64 mmol if 60%) in 10 mL of CH₂Cl₂. After warming to room temperature and stirring overnight, the solution was added to 20 mL of a saturated NaHCO₃ solution. The aqueous layer was separated and extracted with CH₂Cl₂ (2 x 10 mL). The pooled organic layers were then dried (MgSO₄) and concentrated. The residue was subjected to flash column chromatography (silica gel, 10% acetone/hexane and 15% acetone/hexane) affording the sulfoxide (632 mg, 55%) as a white solid, mp 123-126°C.

20,20-ethylenedioxy-3 α -hydroxy-3 β -[[2-(phenylsulfinyl)-2-phenyl]ethyl]-5 α -pregnane

A solution of diisopropylamine (Aldrich, freshly distilled from CaH₂; 0.5 mL, 361 mg, 3.57 mmol) in 2 mL of dry THF was cooled to -10°C and treated with a 1.6 M solution of *n*-BuLi in hexanes (Aldrich; 1.0 mL, 1.6 mmol) added dropwise via syringe. After 10 m, the reaction was cooled to -75°C and a solution of benzyl phenyl sulfoxide (347 mg, 1.60 mmol) in 5 mL of dry THF was added dropwise via syringe over 30 m. To the resulting deep yellow solution was added 297 mg (0.79 mmol) of solid 20,20-ethylenedioxy-3(R)-5 α -pregnan-3-spiro-2'-oxirane. The reaction was allowed to warm to rt and then warmed to 50°C. After 5 h, the reaction was allowed to cool to rt

and added to 30 mL of ice-cold water. The resulting mixture was extracted with EtOAc (3 x 20 mL). The combined EtOAc layers were back extracted with a sat. NaCl solution, dried (Na₂SO₄) and concentrated. The residue was purified by flash chromatography (silica gel, gradient from 100% CH₂Cl₂ to 20% acetone/CH₂Cl₂.) affording the sulfoxide (405 mg, 86%) as a mixture of two diastereomers (based on two benzylic protons in ¹H NMR).

3 α -Hydroxy-3 β -[[2-(phenylsulfinyl)-2-phenyl]ethyl]-5 α -pregnan-20-one

A solution of 20,20-ethylenedioxy-3 α -hydroxy-3 β -[[2-(phenylsulfinyl)-2-phenyl]ethyl]-5 α -pregnane (1.30 g, 2.21 mmol) in 15 mL of THF was cooled in an ice/water bath and an aqueous 1N HCl solution (3 mL) was added followed by 2 mL of acetone. After stirring at rt for 70 min, the reaction was recooled to 0°C and added to an EtOAc/water mixture containing 6 mL of a sat. NaHCO₃ solution. The aqueous layer was extracted twice with EtOAc and the combined organic layers were extracted with a sat. NaCl solution, dried (Na₂SO₄) and concentrated. The residue was carried on to the next step without purification.

3 α -Hydroxy-3 β -(E)-(2-phenylethenyl)-5 α -pregnan-20-one

A suspension of 3 α -hydroxy-3 β -[[2-(phenylsulfinyl)-2-phenyl]ethyl]-5 α -pregnan-20-one (963 mg, 1.76 mmol) in 6 mL of *p*-cymene containing 0.95 mL of 2,4,6-collidine was heated at 135°C for 1 hr. After standing overnight at 0°C, the product had precipitated and was isolated by filtration. The crude product was washed with cold *p*-cymene (3 x 5 mL) and hexane (a total of 120 mL) and afforded 445 mg of the title compound as a white solid, mp 209-213°C.

Example 45

3 α -Hydroxy-2 β -trimethylsilylethynyl-5 α -pregnan-20-one

A solution of trimethylsilylacetylene (0.5 mL, 0.347 g, 3.54 mmol) in 4 mL of dry THF was cooled to -78°C and treated with a 2.5 M solution of *n*-BuLi in hexanes. Neat BF₃-Et₂O (0.3 mL, 0.346 g, 2.44 mmol) was added via syringe. After stirring at -78°C for 5m, a solution of 20,20-ethylenedioxy-5 α -pregnan-2 α ,3 α -epoxide (557 mg, 1.54 mmol) in 3 mL of dry THF was added over 12m. After an additional 2.5h, the reaction was added to a sat. NH₄Cl solution. The resulting mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were washed with a brine solution, dried (Na₂SO₄) and concentrated under reduced pressure. The crude reaction mixture was dissolved in 10 mL of acetone, cooled in an ice/water bath and treated with a 1N HCl solution (1 mL). After 1h at rt, the reaction was added to an ether/water mixture containing 1 mL of a sat. NaHCO₃ solution. The aqueous layer was washed twice with ether and the pooled ether layers were washed with a sat. NaCl solution, dried (Na₂SO₄) and concentrated. Flash column chromatography (silica gel, 12.5 % acetone/hexane) afforded 249 mg of the title compound as a white solid, mp 164-167°C.

The procedure above was used for the preparation of 3 α -hydroxy-2 β -(3'-methoxy-1'-propynyl)-5 α -pregnan-20-one.

The hydrolysis of the trimethylsilyl compound with K₂CO₃/MeOH gave 3 α -hydroxy-2 β -ethynyl-5 α -pregnan-20-one as a white solid, m.p. 179-189°C (decomp.).

Example 46

3 α ,21-Dihydroxy-3 β -ethynyl-5 β -pregnan-20-one

a. 21-Bromo-3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one

5 A solution of 3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one (3 g, 8.77 mmol) in MeOH (110 mL) was treated with two drops of HBr (48%), followed by bromine (0.5 mL, 10.8 mmol). The mixture was stirred at room temperature for 1 hr and was poured into ice-water. The separated solid was collected by filtration, washed with water, and dried (3.2 g). This semi-dried solid was then dissolved in EtOAc and dried over anhyd. MgSO₄. Filtration and removal of the solvent gave the crude bromo derivative. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:EtOAc mixture (4:1) gave 21-bromo-3 β -ethynyl-3 α -hydroxy-5 β -pregnan-20-one (3.2 g).

b. 3 α ,21-Dihydroxy-3 β -ethynyl-5 β -pregnan-20-one

15 A solution of the above bromo derivative (3.2 g) in acetone (100 mL) was treated with trifluoroacetic acid (5.8 mL, 76 mmol) and triethylamine (8.5 mL). The mixture was refluxed for 30 min. and then trifluoroacetic acid sodium salt (10 g) was added in portions over a period of 10 hr. After cooling to room temperature, a solution of sat. NaHCO₃ was added. The solvent was removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:EtOAc mixture (3:2) gave 3 α ,21-dihydroxy-3 β -ethynyl-5 β -pregnan-20-one (1.6 g). mp 156-157°C; TLC R_f (hexane:acetone 3:1) = 0.2.

Example 47

3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one

5 A solution of 4-iodoacetophenone (1.22 g, 4.44 mmol), 3 α ,21-dihydroxy-3 β -ethynyl-5 β -pregnan-20-one (1.59 g, 4.44 mmol) in dry degassed triethylamine (7 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)palladium chloride (15 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH₂Cl₂ (30 mL) was added and the mixture was stirred at 23°C for 1.5 hr. TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (4:1) gave 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one (1.3 g) as a colorless solid; mp 181-183 °C, TLC R_f (hexane:acetone 3:2) = 0.14.

Example 48

15 *3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate sodium salt*

a. *3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate*

20 A solution of 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one (1.3 g, 6.76 mmol) in pyridine (8 mL) was treated with succinic anhydride (680 mg, 2.5 mmol) and 4-(N,N-dimethyl)aminopyridine (25 mg). The mixture was heated to 70-75°C for 2.5 hr. TLC showed 100% conversion. Pyridine was removed and the residue was extracted with EtOAc. The organic layer was washed with 0.1N HCl, water, and brine. After drying over anhyd. MgSO₄, the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of

25

-56-

CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:acetone mixture (7:3) gave 3 β -(4'-acetylphenyl-ethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate (1.4 g).

5 ***b. 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemisuccinate sodium salt***

A mixture of the above hemisuccinate (1.5 g, 2.6 mmol), NaHCO₃ (220 mg, 2.6 mmol), water (10 mL), and CH₂Cl₂ (16 mL) was stirred at room temperature for 1 hr. The solvent was removed and the residue was freeze-dried to yield the sodium salt as a colorless solid (1.4 g).

10

Example 49

3 α ,21-Dihydroxy-3 β -ethynyl-5 α -pregnan-20-one

a. 21-Bromo-3 β -ethynyl-3 α -hydroxy-5 α -pregnan-20-one

15 A solution of 3 β -ethynyl-3 α -hydroxy-5 α -pregnan-20-one (2.3 g, 6.72 mmol) in MeOH (80 mL) was treated with two drops of HBr (48%), followed by bromine (0.4 mL, 7.73 mmol). The mixture was stirred at room temperature for 1 hr and was poured into ice-water. The separated solid was collected by filtration, washed with water, and dried (2.5 g). This semi-dried solid was then dissolved in EtOAc and dried over anhyd. MgSO₄. Filtration and removal of the solvent gave the crude bromo derivative. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with hexane:EtOAc mixture (85:15) gave 21-bromo-3 β -ethynyl-3 α -hydroxy-5 α -pregnan-20-one (2.1 g).

20

b. 3 α ,21-Dihydroxy-3 β -ethynyl-5 α -pregnan-20-one

25 A solution of the above bromo derivative (2.1 g, 5 mmol) in acetone (40 mL) was treated with trifluoroacetic acid (3.8 mL, 50 mmol) and triethylamine (5.5 mL). The mixture was refluxed for 30 min. and then

-57-

trifluoroacetic acid sodium salt (10 g) was added in parts over a period of 10 hr. After cooling to room temperature, a solution of sat. NaHCO_3 was added. The solvent was removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO_4 , the solution was filtered and evaporated to yield the crude product (1.6 g). This crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with hexane:EtOAc mixture (7:3) gave $3\alpha,21$ -dihydroxy- 3β -ethynyl- 5α -pregnan-20-one (1.5 g), mp 214-218°C; TLC R_f (hexane:acetone 7:3) = 0.33.

10

Example 50

3β -(4'-Acetylphenylethynyl)- $3\alpha,21$ -dihydroxy- 5α -pregnan-20-one

A solution of 4-iodoacetophenone (962 mg, 4 mmol), $3\alpha,21$ -dihydroxy- 3β -ethynyl- 5α -pregnan-20-one (1.2 g, 4 mmol) in dry degassed triethylamine (7 mL) was stirred under argon at 23°C. Bis(triphenyl-phosphine)palladium chloride (15 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH_2Cl_2 (25 mL) was added and the mixture was stirred at 23°C for 1.5 hr. TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (7:3) gave 3β -(4'-acetylphenylethynyl)- $3\alpha,21$ -dihydroxy- 5α -pregnan-20-one (750 mg) as a colorless solid; mp 222-225°C, TLC R_f (hexane:acetone 4:1) = 0.13.

Example 51

3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate sodium salt

5 ***a. 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate***

10 A solution of 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one (276 mg, 1.4 mmol) in pyridine (4 mL) was treated with succinic anhydride (680 mg, 2.7 mmol) and 4-(N,N-dimethyl)aminopyridine (20 mg). The mixture was heated to 70-75°C for 2.5 hr. TLC showed 100% conversion. Pyridine was removed in vacuo and the residue was extracted with EtOAc. The organic layer was washed with 0.1N HCl, water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with
15 hexane:acetone mixture (7:3) gave 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate (400 mg).

b. 3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemisuccinate sodium salt

20 A mixture of the above hemisuccinate (400 mg, 0.7 mmol), NaHCO₃ (60 mg, 0.7 mmol), water (3 mL), and CH₂Cl₂ (5 mL) was stirred at room temperature for 1 hr. The solvent was removed and the residue was freeze-dried to yield the sodium salt as a colorless solid (390 mg).

Example 52

3 α -Hydroxy-3 β -(3-pyridyl)ethynyl-5 β -pregnan-20-one

A solution of 3-bromopyridine (70 mg, 0.44 mmol), 3 β -ethynyl-3 α -hydroxy-5 α -pregnan-20-one (150 mg, 0.44 mmol) in dry degassed diethylamine (1 mL) was stirred under argon at 23°C. Bis(triphenylphosphine)palladium chloride (10 mg) and CuI (5 mg) were added and the mixture was stirred at this temp. for 45 min. CH₂Cl₂ (4 mL) was added and the mixture was stirred at 23°C for 1.5 hr. TLC showed 100% conversion of the starting material, hence, the solvent was removed and the residue was purified by chromatography on silica gel. Elution with hexane:acetone (3:1) gave 3 α -hydroxy-3 β -(3-pyridyl)ethynyl-5 β -pregnan-20-one (30 mg) as a colorless solid; mp 230-35°C, TLC R_f (hexane:acetone 7:3) = 0.24.

Example 53

21-Bromo-3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-5 β -pregnan-20-one

A solution of 3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-5 β -pregnan-20-one (483 mg, 1.3 mmol) in MeOH (20 mL) was heated to 33°C and was treated with two drops of HBr (48%), followed by bromine (1.43 mmol, 0.73 mL). The mixture was stirred at 37°C for 1 hr and was poured into ice-water. The separated solid was collected by filtration, washed with water, and dried. This semi-dried solid was then dissolved in EtOAc and dried over anhyd. MgSO₄. Filtration and removal of the solvent gave the crude 21-bromo-3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-5 β -pregnan-20-one (322 mg).

Example 54

3 α -Hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(1,2,3-triazol-2-yl)-5 β -pregnan-20-one and 3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(1,2,3-triazol-1-yl)-5 β -pregnan-20-one

5 A suspension of NaH (30 mg, 95%, 1.2 mmol) in THF (10 mL) was treated with a solution of 1,2,3-triazole (69 mg, 1 mmol) in THF (10 mL) at room temperature. After stirring the mixture for 30 min. a solution of the crude bromo derivative of Example 53 (162 mg, 0.37 mmol) in THF (10 mL) was added. The stirring was continued at room temperature for 1.5 hr. Sat.
10 NH₄Cl soln. was added and the solvent was removed. The residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO₄ the solution was filtered and evaporated to yield the crude product (250 mg). This crude product was then dissolved in a small amount of CH₂Cl₂ and poured on a column of silica gel. Elution with
15 CH₂Cl₂:acetone (6:4) mixture gave 3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one (40 mg) as a first fraction; mp 188-191°C; TLC R_f (CH₂Cl₂:acetone 6:4) 0.56. Further elution with the same solvent mixture yielded 3 α -hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(1H-1,2,3-triazol-1-yl)-5 β -pregnan-20-one (40 mg); mp 135-140°C; TLC R_f
20 (CH₂Cl₂:acetone 6:4) 0.34.

Example 55

3 β -(4'-Hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-11,20-dione

25 A solution of 3-butyn-1-ol (0.4 mL, 5.2 mmol) in dry THF (15 mL) was treated with n-BuLi (4 mL, 2.5M in THF, 10 mmol) at -65°C. After stirring the mixture at -78°C for 0.5 hr, a solution of 5 β -pregnan-3,11,20-trione, cyclic 20-(1,2-ethanediyl acetal) (800 mg, 2.14 mmol) in THF (20 mL)

-61-

was added and the mixture was stirred at -78°C for 1 hr. The cooling bath was removed and the stirring was continued at room temperature for 45 min. The mixture was then quenched with NH_4Cl solution (5 mL). The solvent was removed the residue was then dissolved in acetone (30 mL). After adding 2N HCl (7 mL) the solution was stirred at rt for 15 min. Sat. NaHCO_3 soln. was added to neutralize the acid. The solvents were removed and the residue was extracted with EtOAc. The organic layer was washed with water, and brine. After drying over anhyd. MgSO_4 the solution was filtered and evaporated to yield the crude product. This crude product was then dissolved in a small amount of CH_2Cl_2 and poured on a column of silica gel. Elution with toluene:acetone mixture (3:1) gave the unreacted butynol as a first fraction. Further elution with the same solvent mixture yielded 3α -(4'-hydroxy-1'-butynyl)- 3β -hydroxy- 5β -pregnan-11,20-dione(100 mg), and then 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5β -pregnan-11,20-dione(400 mg) as a colorless solid; mp 158 - 162°C ; TLC R_f (toluene:acetone 3:1) = 0.16.

It will be obvious to one skilled in the art that the above described compounds may be present as mixtures of diastereomers which may be separated into individual diastereomers. Resolution of the diastereomers may be conveniently accomplished by gas or liquid chromatography or isolation from natural sources. Unless otherwise specified herein, reference in the specification and claims to the compounds of the invention, as discussed above, is intended to include all isomers, whether separated or mixtures thereof.

Where isomers are separated, the desired pharmacological activity will often predominate in one of the diastereomers. As disclosed herein, these compounds display a high degree of stereospecificity. In particular, those compounds having the greatest affinity for the GABA receptor complex are those with 3β -substituted- 3α -hydroxypregnane steroid skeletons.

The compounds of and used in the invention, that being the nontoxic, pharmaceutically acceptable, natural and synthetic, direct acting and "prodrug" forms of progesterone, deoxycorticosterone, and androstane metabolites, have

-62-

hitherto unknown activity in the brain at the GABA_A receptor complex. The present invention takes advantage of the discovery of this previously unknown mechanism and activity.

5 The pharmaceutical compositions of this invention are prepared in conventional dosage unit forms by incorporating an active compound of the invention or a mixture of such compounds, with a nontoxic pharmaceutical carrier according to accepted procedures in a nontoxic amount sufficient to produce the desired pharmacodynamic activity in a subject, animal or human. Preferably, the composition contains the active ingredient in an active, but
10 nontoxic amount, selected from about 1 mg to about 500 mg of active ingredient per dosage unit. This quantity depends on the specific biological activity desired and the condition of the patient. Desirable objects of the compositions and methods of this invention are in the treatment of stress, anxiety, PMS, PND, and seizures such as those caused by epilepsy to ameliorate or prevent the attacks of anxiety, muscle tension, and depression
15 common with patients suffering from these central nervous system abnormalities. An additional desirable object of the composition and methods is to treat insomnia and produce hypnotic activity. Another desirable object of the compounds and methods is to induce anesthesia, particularly by
20 intravenous administration.

 The pharmaceutical carrier employed may be, for example, either a solid, liquid, or time release (see e.g. Remington's Pharmaceutical Sciences, 14th Edition, 1970). Representative solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid,
25 microcrystalline cellulose, polymer hydrogels and the like. Typical liquid carriers are propylene glycol, glycofurol, aqueous solutions of cyclodextrins, syrup, peanut oil, and olive oil and the like emulsions. Similarly, the carrier or diluent may include any time-delay material well known to the art, such as glycerol monostearate or glycerol distearate alone or with wax, microcapsules,
30 microspheres, liposomes, and/or hydrogels.

-63-

A wide variety of pharmaceutical forms can be employed. Thus, when using a solid carrier, the preparation can be plain milled micronized, in oil, tableted, placed in a hard gelatin or enteric-coated capsule in micronized powder or pellet form, or in the form of a troche or lozenge. The compounds of and used in the invention may also be administered in the form of suppositories for rectal administration. Compounds may be mixed in material such as cocoa butter and polyethylene glycols or other suitable non-irritating material which is solid in rt but liquid at the rectal temperature. When using a liquid carrier, the preparation can be in the form of a liquid, such as an ampule, or as an aqueous or nonaqueous liquid suspension. Liquid dosage forms also need pharmaceutically acceptable preservatives and the like. In addition, because of the low doses that will be required as based on the data disclosed herein, parental administration, nasal spray, sublingual and buccal administration, and timed release skin patches are also suitable pharmaceutical forms for topical administration.

The method of producing anxiolytic, anticonvulsant, mood altering (such as anti-depressant) or hypnotic activity, in accordance with this invention, comprises administering to a subject in need of such activity a compound of the invention, usually prepared in a composition as described above with a pharmaceutical carrier, in a nontoxic amount sufficient to produce said activity.

During menses, the levels of excreted metabolites vary approximately fourfold (Roszczewska, *et al.*). Therefore, therapy for controlling symptoms involves maintaining the patient at a higher level of progesterone metabolites than normal in the premenstrual state of PMS patients. Plasma levels of active and major metabolites are monitored during pre-menses and post-menses of the patient. The amount of the compounds of the invention administered, either singly or as mixtures thereof are thus calculated to reach a level which will exert GABA_A-receptor activity equal or higher than the level of progesterone metabolites in the normal subject during the premenses state.

-64-

The route of administration may be any route that effectively transports the active compound to the GABA_A receptors that are to be stimulated. Administration may be carried out parenterally, enterally, rectally, intravaginally, intradermally, intramuscularly, sublingually, or nasally; the oral, intramuscular, and dermal routes are preferred. For example, one dose in a skin patch may supply the active ingredient to the patient for a period of up to one week. However, the parenteral route is preferred for status epilepticus.

Potency and Efficacy at the GR Site

The *in vitro* and *in vivo* experimental data show that the naturally-occurring metabolites of progesterone/deoxycorticosterone and their derivatives interact with high affinity at a novel and specific recognition site on the GR complex to facilitate the conductance of chloride ions across neuronal membranes sensitive to GABA (Gee *et al.*, 1987 Harrison *et al.*, 1987).

To those skilled in the art, it is known that the modulation of [³⁵S]t-butylbicyclophosphorothionate ([³⁵S]TBPS) binding is a measure of the potency and efficacy of drugs acting at the GR complex, which drugs may be of potential therapeutic value in the treatment of stress, anxiety, and seizure disorders (Squires, R.F., *et al.*, "[³⁵S]t-Butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to a gamma aminobutyric acid-A and ion recognition site," *Mol. Pharmacol.*, 23:326, 1983; Lawrence, L.J., *et al.*, "Benzodiazepine anticonvulsant action: gamma-aminobutyric acid-dependent modulation of the chloride ionophore," *Biochem. Biophys. Res. Comm.*, 123:1130-1137, 1984; Wood, *et al.*, "In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonist/antagonists," *Pharmacol. Exp. Ther.*, 231:572-576, 1984). We performed several experiments to determine the nature of the modulation of [³⁵S]TBPS as affected by the compounds of the invention. We found that these compounds interact with a novel site on the GR complex which does not

-65-

overlap with the barbiturate, the benzodiazepine or any other previously known sites. Furthermore, these compounds have high potency and efficacy at the GR complex, with stringent structural requirements for such activity. Preferred compounds which are useful in the present invention have an IC₅₀ of 2 μ M or less in the [³⁵S]TBPS binding assay described herein below.

The procedures for performing this assay are fully discussed in: (1) Gee, *et al.*, 1987; and (2) Gee, K.W., L.J. Lawrence, and H.I. Yamamura, "Modulation of the chloride ionophore by benzodiazepine receptor ligands: influence of gamma-aminobutyric acid and ligand efficacy," *Molecular Pharmacology* 30:218, 1986. These procedures were performed as follows:

Brains from male Sprague-Dawley rats were removed immediately following sacrifice and the cerebral cortices dissected over ice. A P₂ homogenate was prepared as previously described (Gee, *et al.*, 1986). Briefly, the cortices were gently homogenized in 0.32 M sucrose followed by centrifugation at 1000 x g for 10 minutes. The supernatant was collected and centrifuged at 9000 x g for 20 minutes. The resultant P₂ pellet was suspended as a 10% (original wet weight/volume) suspension in 50 mM Na/K phosphate buffer (pH 7.4) 200 mM NaCl to form the homogenate.

One hundred microliter (ml) aliquots of the P₂ homogenate (0.5 milligrams (mg) protein) were incubated with 2 nanomolar (nM) [³⁵S]TBPS (70-110 curies/millimole; New England Nuclear, Boston, MA) in the presence or absence of the naturally occurring steroids or their synthetic derivatives to be tested. The tested compounds were dissolved in dimethylsulfoxide (Baker Chem. Co., Phillipsbury, NJ) and added to the incubation mixture in 5 μ L aliquots. The incubation mixture was brought to a final volume of 1 mL with buffer. Non-specific binding was defined as binding in the presence of 2 mM TBPS. The effect and specificity of GABA (Sigma Chem. Co., St. Louis, MO) was evaluated by performing all assays in the presence of GABA plus (+)bicuculline (Sigma Chem. Co.). Incubations maintained at 25°C for 90 minutes (steady state conditions) were terminated by rapid filtration through glass fiber filters (No. 32, Schleicher

and Schuell, Keene, NH). Filter-bound radioactivity was quantitated by liquid scintillation spectrophotometry. Kinetic data and compound/[³⁵S]TBPS dose-response curves were analyzed by nonlinear regression using a computerized iterative procedure to obtain rate constants and IC₅₀ (concentration of compound at which half-maximal inhibition of basal [³⁵S]TBPS binding occurs) values.

The experimental data obtained for this assay are also published in Gee, *et al.*, 1987. The data discussed in this reference are shown as plots in FIGS. 1A and 1B. These plots show the effect of (+)bicuculline on the pregnane steroid alphaxalone (1A) and GABA (1B) modulation of 2 nM [³⁵S]TBPS binding to rat cerebral cortex. In these figures, (○) represents control without bicuculline; (●) represents 0.5 μM bicuculline; (□) represents 1.0 μM bicuculline; (■) represents 2.0 μM bicuculline; and (Δ) represents 3.0 μM bicuculline. In this experiment, the effect of (+)bicuculline on the ability of alphaxalone or GABA to inhibit the binding of [³⁵S]TBPS was determined. Bicuculline is known to be a competitive antagonist of GABA and a classical parallel shift in the dose-response curves is observed in FIG. 1B. In contrast, the steroid binding site identified by this work is distinct from the GABA/bicuculline site in FIG. 1A. The shift in dose-response curves induced by bicuculline when the inhibition of [³⁵S]TBPS binding is caused by alphaxalone is not parallel. This indicates that the GABA and steroid sites do not overlap.

A second set of experiments were performed to demonstrate that steroids, barbiturates and benzodiazepines do not share common binding site on the GABA receptor. Figure 2 shows the time course for the dissociation of [³⁵S] TBPS from rat cortical P₂ homogenates initiated by the addition of 2 μM TBPS (■), 1 μM 3α-hydroxy-5α-pregnan-20-one (□), 100 μM Na pentobarbital (●) and 1 μM 3α-OH-5α-pregnan-20-one + 100 μM Na pentobarbital (○). The assay was performed in accordance with the procedures outlined above. These kinetic data show that the dissociation of [³⁵S] TBPS binding initiated by saturating concentration of 3α-hydroxy-5α-

-67-

pregnan-20-one is potentiated by 100 μ M Na pentobarbital. This effect is an indication that 3 α -OH-5 α -pregnan-20-one (steroid) and pentobarbital (barbiturate) bind to independent sites.

The third set of experiments examined the interactions between 3 α -hydroxy-5 α -pregnan-20-one and Na pentobarbital in the potentiation of (3 H) flunitrazepam (FLU) binding. These experiments further support the claim that steroids do not share common site of action with benzodiazepines and barbiturates. In this series of experiments, the effect of varying concentrations of 3 α -hydroxy-5 α -pregnan-20-one on (3 H) FLU binding in the presence or absence of a maximally stimulating concentration of Na pentobarbital. Since Na pentobarbital has greater maximum efficacy than that of 3 α -hydroxy-5 α -pregnan-20-one in potentiating (3 H)FLU binding, 3 α -hydroxy-5 α -pregnan-20-one should ultimately antagonize the effect of Na pentobarbital if the two interact competitively on the same site. This is not what was observed (Fig. 3). Thus, the data further support our conclusion that certain steroids including the compounds of and used in the invention interact with a novel site distinct from the barbiturate or BZ regulatory site on the GR complex. Because of this independent site of action, it is anticipated that these steroid compounds will have therapeutic profiles different from those of barbiturates and BZs.

Various compounds were screened to determine their potential as modulators of [35 S]TBPS binding *in vitro*. These assays were performed in accordance with the above discussed procedures. Based on these assays, we have established the structure-activity requirements for their specific interaction at the GR complex and their rank order potency and efficacy. Figure 4 provides [35 S]TBPS inhibition of curves of 3 α -hydroxy-5 α -pregnan-20-one (3 α ,5 α -P), 3 α ,21-dihydroxy-5 α -pregnan-20-one (5 α -THDOC) and R5020 (promogesterone) as experimental examples, while Table 1 provides IC₅₀ and maximum inhibition of numerous compounds, including examples of those claimed in the application. IC₅₀ is defined as concentration of compounds to inhibit 50% of control [35 S]TBPS binding. It is an indication

of a compound's *in vitro* potency. Maximum inhibition is an indication of a compound's *in vitro* efficacy.

Table 1

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
5	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one	4	92
	3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one	5	93
	3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -19-norpregnan-20-one	6	90
10	3 β -(4'-Carboxyphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one ethyl ester	7	79
	3 β -(4'-Carboxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one ethyl ester	8	98
	3 β -(4-Hydroxybutyn-1-yl)-3 α -hydroxy-5 β -pregnan-20-one	13	103
15	3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	14	103
	3 β -(4'-Carboxyphenyl)ethynyl-3 α -hydroxy-19-nor-5 β -pregnan-20-one ethyl ester	15	94
	3 β -(4-Acetoxybutyn-1-yl)-3 α -hydroxy-5 β -pregnan-20-one	20	96
20	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one	22	99
	3 β -(4-Hydroxybutyn-1-yl)-3 α -hydroxy-5 β -19-norpregnan-20-one	22	102
	3 β -(3'-Methoxy-1'-propynyl)-3 α -hydroxy-5 β -pregnan-20-one	27	105
	3 β -(4'-Dimethylaminophenyl)ethynyl-5 β -pregnan-20-one	28	77
25	3 β -[3-(2-propynyloxy)propyn-1-yl]-3 α -hydroxy-5 β -pregnan-20-one	28	105
	3 β -(4-Hydroxybutyn-1-yl)-3 α -hydroxy-5 α -pregnan-20-one	35	95
	3 α -Hydroxy-5 α -pregnan-20-one	37	95
	3 β -(4'-Biphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	43	83
30	3 α -Hydroxy-3 β -(4'-nitrophenyl)ethynyl-5 β -pregnan-20-one	46	103
	3 α -Hydroxy-21-(2H-1,2,3,4-tetrazol-2-yl)-5 β -pregnan-20-one	46	78

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
	3 α -Hydroxy-3 β -(4'-methoxyphenyl)ethynyl-5 β -pregnan-20-one	47	89
	3 β -(4'-Trifluoromethylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	52	87
5	3 β -(5-Acetylthien-2-yl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	52	89
	21-(1-Benzimidazolyl)-3 α -hydroxy-5 β -pregnan-20-one	53	100
	3 β -(4-Hydroxybutyn-1-yl)-3 α -hydroxy-21-(1-imidazolyl)-5 β -pregnan-20-one	54	93
10	3 α -Hydroxy-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one	56	79
	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(1,2,3-triazol-2-yl)-5 β -19-norpregnan-20-one	56	93
	3 β -(4'-Chlorophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	58	89
	3 β -(5'-Hydroxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	58	100
15	3 α -Hydroxy-3 β -(thien-2-yl)ethynyl-5 β -pregnan-20-one	59	100
	3 β -(3'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	62	100
	3 α -Hydroxy-21-[1H-(4-methyl-5-carboxyl)imidazol-1-yl]-5 β -pregnan-20-one	62	100
20	3 α -Hydroxy-3 β -[3'-(2H-1,2,3-triazol-2-yl)-1-propynyl]-5 β -pregnan-20-one	66	98
	3 α -Hydroxy-21-(9H-1,2,3-purin-9-yl)-5 β -pregnan-20-one	69	59
	3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 β -pregnan-20-one	71	103
	3 α -Hydroxy-21-(imidazol-1-yl)-5 α -pregnan-20-one	71	99
25	3 α -Hydroxy-21-(imidazol-1-yl)-5 β -pregnan-20-one	73	57
	3 β -(4'-Cyanophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	73	92
	3 α ,21-Dihydroxy-5 α -pregnan-20-one (5 α -THDOC)	76	100
	3 α -Hydroxy-3 β -(pentafluorophenyl)-ethynyl-5 β -pregnan-20-one	79	69
30	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(1,2,3-triazol-1-yl)-5 β -pregnan-20-one	79	96
	3 β -Ethynyl-3 α -hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one	80	103

-70-

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
	3 α -Hydroxy-3 β -[3'-(1H-pyrazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	81	98
	3 α -Hydroxy-3 β -methyl-21-(2H-1,2,3-triazol-2-yl)-5 α -pregnan-20-one	85	99
5	3 β -[4'-(N,N-Diethylcarboxamidophenyl)ethynyl]-3 α -hydroxy-5 β -pregnan-20-one	87	94
	3 α -Hydroxy-3 β -(4'-methylphenyl)ethynyl-5 β -pregnan-20-one	88	84
	3 α -Hydroxy-3 β -(6-oxo-1-heptynyl)-5 β -pregnan-20-one	90	101
10	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(1,2,4-triazol-1-yl)-5 β -pregnan-20-one	93	96
	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(tetrazol-1-yl)-5 β -pregnan-20-one	93	101
	3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 β -pregnan-20-one	94	104
15	3 β -(5'-Acetoxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	96	98
	3 α -Hydroxy-21-(1H-3,5-dimethylpyrazolyl)-5 β -pregnan-20-one	96	77
	3 α -Hydroxy-21-(1'-imidazolyl)-3 β -methyl-5 α -pregnan-20-one	97	95
	3 α -Hydroxy-3 β -(phenylethynyl)-5 β -pregnan-20-one	98	101
20	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(1'-imidazolyl)-5 β -19-norpregnan-20-one	98	98
	3 α -Hydroxy-21-(1'-pyrazolyl)-5 α -pregnan-20-one	100	98
	3 β -(2'-Hydroxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	101	83
25	3 α -Hydroxy-3 β -(3'-phenyl-1'-propynyl)-5 β -pregnan-20-one	103	95
	3 β -Ethynyl-3 α -Hydroxy-21-(1'-pyrazolyl)-5 β -pregnan-20-one	106	99
	Sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-5 β -pregnan-20-on-21-yl] thiosulfate	107	97
	3 α -Hydroxy-3 β -(2'-pyridyl)ethynyl-5 β -pregnan-20-one	108	98
30	3 β -(2,4-Difluorophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	109	102
	3 β -Benzyl-3 α -hydroxy-5 β -pregnan-20-one	109	102

-71-

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
	21-(1'-Benzimidazolyl)-3 α -hydroxy-3 β -methyl-5 α -pregnan-20-one	109	95
	3 α -Hydroxy-21-(1'-pyrazolyl)-3 β -methyl-5 α -pregnan-20-one	115	98
	3 α -Hydroxy-3 β -(5'-oxo-1-hexynyl)-5 β -pregnan-20-one	118	101
5	3 α -Hydroxy-21-(pyrazol-1-yl)-5 β -pregnan-20-one	121	67
	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-21-(1,2,3-triazol-1-yl)-5 β -19-norpregnan-20-one	124	95
	3 α -Hydroxy-3 β -methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one	125	105
10	3 β -Ethyne-3 α -hydroxy-21-(1',2',4'-triazolyl)-5 β -pregnan-20-one	127	98
	3 β -(4'-Cyanobutynyl)-3 α -hydroxy-5 β -pregnan-20-one	131	86
	Sodium S-[3 α -hydroxy-3 β -(methoxymethyl)-5 β -pregnan-20-on-21-yl] thiosulfate	132	103
15	Sodium S-(3 α -hydroxy-5 α -pregnan-20-on-21-yl)thiosulfate	133	90
	3 α -Hydroxy-3 β -(2'-phenylethyl)-5 β -pregnan-20-one	135	98
	3 α -Hydroxy-3 β -methyl-21-(1',2',3'-triazol-1'-yl)-5 α -pregnan-20-one	136	99
	3 α -Hydroxy-3 β -[3'-hydroxypropynyl]-5 β -pregnan-20-one	137	93
20	3 α -Hydroxy-3 β -(3-pyridyl)ethynyl-5 β -pregnan-20-one	138	100
	3 α -Hydroxy-3 β -[3'(RS)-hydroxybutynyl]-5 α -pregnan-20-one	144	99
	3 α -Hydroxy-3 β -(4-pyridyl)ethynyl-5 β -pregnan-20-one	149	103
	3 α -Hydroxy-21-(1',2',4'-triazol-1-yl)-5 β -pregnan-20-one	151	60
25	Sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl)thiosulfate	151	101
	3 β -(5'-Cyanopentynyl)-3 α -hydroxy-5 β -pregnan-20-one	158	100
	3 β -(4'-Acetoxyacetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	171	91
	3 α -Hydroxy-3 β -phenylpropyl-5 β -pregnan-20-one	173	92
30	3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 α -pregnan-20-one	178	101
	3 α -Hydroxy-3 β -[3'(RS)-hydroxybutynyl]-5 β -pregnan-20-one	202	102

-72-

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
	3 β -(6-Hydroxyhexyn-1-yl)-3 α -hydroxy-5 β -pregnan-20-one	222	99
	3 α -Hydroxy-21-[1H-(2-methyl)imidazol-1-yl]-5 β -pregnan-20-one	222	95
5	3 β -(3'-Acetoxypropyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	224	104
	3 α -hydroxy-21-(1'H-1,2,3,4-tetrazol-1'-yl)-5 β -pregnan-20-one	227	60
	3 α -Hydroxy-21-(2-formylimidazol-1-yl)-5 β -pregnan-20-one	213	81
	3 α -Hydroxy-3 β -(2'-methoxyphenyl)ethynyl-5 β -pregnan-20-one	238	99
10	3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-11,20-dione	268	102
	3 β -[(3',4'-Dimethoxyphenyl)ethynyl]-3 α -hydroxy-5 β -pregnan-20-one	283	106
15	3 α -Hydroxy-21-[1H-(4-nitro)imidazol-1-yl]-5 β -pregnan-20-one	267	71
	Sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl)thiosulfate	268	88
	3 β -(6'-Acetoxyhexyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	306	99
	Sodium S-(3 α -hydroxy-3 β -trifluoromethyl-5 β -19-norpregnan-20-on-21-yl) thiosulfate	325	98
20	3 α -Hydroxy-3 β -phenyl-5 β -pregnan-20-one	382	86
	3 β -(3'-Hydroxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	407	99
	3 α -Hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(1,2,3-triazol-2-yl)-5 β -pregnan-20-one	430	107
25	3 α -Hydroxy-21-(7'H-purin-7'-yl)-5 β -pregnan-20-one	430	71
	3 α -Hydroxy-21-(1'-uracil)-5 α -pregnan-20-one	434	90
	3 α -Hydroxy-3 β -[3'-(pyrid-4-yloxy)-1'-propynyl]-5 β -pregnan-20-one	465	94
30	3 β -[2-(3',4'-Dimethoxyphenyl)ethyl]-3 α -hydroxy-5 β -pregnan-20-one	507	66
	3 α -Hydroxy-3 β -(3'-hydroxyphenyl)-ethynyl-5 β -pregnan-20-one	619	98
	3 α -Hydroxy-3 β -[3'-(1H-1,2,3-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	655	102

	COMPOUND	IC ₅₀ (nM)	IMAX (%)
	3 α -Hydroxy-3 β -[3'-(1H-1,2,4-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	843	99
	3 α -Hydroxy-3 β -(3-hydroxypropyn-1-yl)-21-(1,2,3-triazol-1-yl)-5 β -pregnan-20-one	1089	101
5	3 β -[3'-(N,N-dimethylamino)-1'-propynyl]-3 α -hydroxy-5 β -pregnan-20-one	1420	100
	3 β -(4'-Acetoxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	1430	100
	3 β -(4-Hydroxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	1550	88
10	3 α -Hydroxy-2 β -morpholinyl-21-(1H-1,2,4-triazol-1-yl)-5 α -pregnan-20-one	1553	97
	3 α -Hydroxy-3 β -(3'-oxopropynyl)-5 β -pregnan-20-one	1720	76
	3 β -(4'-Carboxamidophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	2240	98
	3 β -(4'-Carboxamidobutynyl)-3 α -hydroxy-5 β -pregnan-20-one	2340	102
15	3 α -Hydroxy-3 β -(3'-oxobutynyl)-5 β -pregnan-20-one	2690	107
	3 α -Hydroxy-3 β -[3'-(N-imidazolyl)-1'-propynyl]-5 β -pregnan-20-one	2720	107
	3 β -(5'-Carboxamidopentynyl)-3 α -hydroxy-5 β -pregnan-20-one	3090	102
	Progesterone	5200	100
20	3 α -Hydroxy-3 β -[3'-oxobutynyl]-5 α -pregnan-20-one	6510	104
	3 β -(4'-Aminophenyl)ethynyl-3 β -hydroxy-5 β -pregnan-20-one	22500	103
	3 β -Hydroxy-5 α -pregnan-20-one (Allopregnanolone)	> 10 ⁶	33
	4-Pregnen-11 β ,21-diol-3,20-dione (Corticosterone)	> 10 ⁶	30
	17 β -Estradiol	na ^a	0
25	Cholesterol	na	0

^ana = not active

As can be seen from Figure 4 and Table 1, 3 α -hydroxy-5 α -pregnan-20-one, 3 α ,21-dihydroxy-5 α -pregnan-20-one and compounds of and used in the invention have low IC₅₀, which is the concentration necessary to achieve 50% maximal inhibition of [³⁵S]TBPS binding, while compounds such as sex
5 steroids (R5020, estradiol and progesterone), glucocorticoids (corticosterone) and cholesterol having a high IC₅₀ are essentially inactive. Thus, it is anticipated that hormonal steroids and cholesterol per se will not have any therapeutic value for the indications described herein. In order to distinguish this unique class of steroids from hormonal steroids, they are now termed
10 neuroactive steroids. However, sex steroids such as progesterone can be metabolized in the body to steroids similar to 3 α -hydroxy-5 α -pregnan-20-one. Thus, progesterone can be considered as a prodrug. The TBPS data correlates with data on ³⁶Cl ion uptake-potentiated by various 3 α -hydroxylated steroids described in Purdy R.H., *et al.*, "Synthesis, Metabolism, and Pharmacological
15 Activity of 3 α -Hydroxy Steroids Which Potentiate GABA-Receptor-Mediated Chloride Ion Uptake in Rat Cerebral Cortical Synaptoneurosomes," *J. Med. Chem* 33:1572-1581 (1990), incorporated herein by reference and these data also correlate with electrophysiological data obtained by measuring steroid's activity to potentiate GABA-induced current in oocytes injected with human
20 GABA receptors as shown in Fig 5. This indicates that the TBPS assay is an approximate measurement of steroids ability to allosterically modulate Cl⁻ channel activity.

Compounds with Limited Efficacy

In as much as the desired therapeutic activity should be available to the
25 patient with the least undesirable side effects, a notable aspect of this invention involves the discovery of agonists with partial activity in those compounds with a 5 α -pregnan-3 α ,20 α -diol, 5 β -pregnan-3 α ,20 β -diol group or the derivatives and prodrugs of these compounds. In addition, a subset of neuroactive steroids other than these two groups also show partial efficacy in

TBPS assay (Table 1). For the patients who desire amelioration of anxiety or convulsions, hypnosis is undesired. For the patients who desire amelioration of insomnia, anesthetic is undesired. The compounds and activities described as agonists with partial activity expected to have the desired effect with minimal undesired effect.

To show the agonists with limited efficacy, the ability of 5α -pregnan- $3\alpha,20\alpha$ -diol and 5β -pregnan- $3\alpha,20\alpha$ -diol to partially modulate the [^{35}S]TBPS binding even at very high concentrations is illustrated (Figure 6).

In addition, the partial ability of these compounds to potentiate GABA-mediated enhancement of Cl^- current were compared to that of 3α -hydroxy- 5α -pregnan-20-one (Figure 7) in *Xenopus* oocyte injected with human GABA_A receptor genes is also shown.

When *Xenopus* oocyte expression system was used to test the limit efficacy property of some neuroactive steroids, the following procedure was performed. *Xenopus laevis* oocytes (stage VI) which had been "defolliculated" using the collagenase digestion method (3 hrs @ $18-23^\circ\text{C}$, 2 mg ml^{-1} collagenase 'A' in Barth's saline with Ca^{2+} salts omitted) were injected with cRNA transcripts of human GABA_A receptor subunit complex $\alpha 1 \beta 1$ and $\gamma 1$. The major GABA_A receptor complex is comprised of $\alpha\beta\gamma$ subunits. Injected oocytes were individually maintained in 96-well plates (200 μL per well of normal Barth's solution supplemented with penicillin 50 IU ml^{-1} , streptomycin 50 mg ml^{-1} and gentomycin 100 mg ml^{-1}) for up to 9 days at $19-20^\circ\text{C}$. Agonist-induced currents were recorded from *Xenopus* oocytes voltage clamped at a holding potential of -60 mV, using an Axoclamp 2 A (Axon Instruments) voltage clamp amplifier in the twin electrode voltage clamp mode. The voltage-sensing and current-passing microelectrodes were filled with 3M KCl, and resistances of 1-3 M Ohms when measured in the standard extracellular saline. The oocytes were continuously superfused with frog Ringer (120 mM NaCl; 2 mM KCl; 1.0 mM CaCl_2 ; 5 mM HEPES pH 7.4) at the rate of 5-7 ml min^{-1} at rt ($17-21^\circ\text{C}$).

-76-

5 All drugs were applied via the perfusion system. Steroids (10^{-2} M) were prepared as concentrated stock solutions either in DMSO or ethanol and then diluted in the Ringer solution at the appropriated concentration. The final DMSO and ethanol concentration was 0.2% v/v, a concentration which had no effect upon GABA evoked responses. Stock solutions of all other drugs were made in Ringer solution. Membrane current responses were low-pass filtered at 100 Hz and recorded onto magnetic tape using an FM tape recorder (Racal Store 4DS) for subsequent analysis.

10 Compounds of and used in the present invention exhibit partial efficacy analogous to those described above also shown in the above tables.

Benefits Over Progesterone

15 The correlations between reduced levels of progesterone and the symptoms associated with PMS, PND, and catamenial epilepsy (Backstrom, *et al.*, 1983; Dalton, K., 1984) led to the use of progesterone in their treatment (Mattson, *et al.*, 1984; and Dalton, 1984). However, progesterone is not consistently effective in the treatment of the aforementioned syndromes. For example, no dose-response relationship exists for progesterone in the treatment of PMS (Maddocks, *et al.*, 1987). These results are predictable when considered in light of the results of our *in vitro* studies which demonstrate that progesterone has very low potency at the GR complex, as seen in Table 1, compared to certain metabolites of progesterone.

20 The beneficial effect of progesterone is probably related to the variable conversion of progesterone to the active progesterone metabolites. The use of specific progesterone metabolites in the treatment of the aforementioned syndromes is clearly superior to the use of progesterone based upon the high potency and efficacy of the metabolites and their derivatives (See Gee, *et al.*, 1987, and Table 1).

No Hormonal Side Effects

It has also been demonstrated that neuroactive steroids lack hormonal side effects by the lack of affinity for the progesterone and other hormonal steroid receptors (Tables 2-5). The data presented were obtained by performing assays in accordance with the procedures described in Gee, *et al.* 1988 previously to determine the effect of progesterone metabolites and their derivatives and the progestin R5020 on the binding of [³H]R5020 to the progesterone receptor in rat uterus (Gee *et al.* 1988).

³H-progesterone (0.15 nM) was incubated with the rat uterus cytosol in the presence of the test compounds. The specific bindings were determined after incubation and compared to the control incubation without the compounds. The data are expressed as percent inhibition of binding. If the compounds bind to the progesterone receptor with high affinity, a 100% inhibition of binding would be expected at the concentration tested.

Various hormonal activities of representative neuroactive steroids were further studied through testing their potential estrogenic, mineralocorticoid and glucocorticoid activities. These activities were analyzed by monitoring the ability of the compounds to inhibit binding of the steroid hormones to their respective hormone receptors. The results are shown in Tables 3-5. They are expressed as percent inhibition of ³H-ligand binding to the various steroid hormone receptors for the compounds at 10⁻⁶ M. Control values are represented by the binding in the absence of testing compounds.

In Table 3, rats were adrenalectomized 3 days prior to sacrifice. To isolate the mineralocorticoid receptor, brain cytosol fractions were prepared as describe in Gee, *et al.* 1988. The drugs were incubated with 3 nM of ³H-aldoosterone (the specific ligand for the mineralocorticoid receptor) in the presence of the selective type II agonist RU28362 (0.5 μM) which blocks ³H-aldoosterone binding to the type II (glucocorticoid) receptors.

Table 2. Inhibition of ^3H -Progesterone Binding to the Bovine Uteral Progesterone Receptors

Competitor (10^{-6}M)	% of Inhibition
R5020	100
5 α -pregnan-3 α -ol-20-one	14
5 α -pregnan-3 α ,21-diol-20-one	13
5 α -pregnan-3 α ,20-diol	6
5 α -pregnan-3 α -ol-3 α ,-methyl-20-one	4
5 β -pregnan-3 α ,21-diol-20-one	6
5 α -pregnan-3 β ,20-trimethyl-3 α ,20-diol	8
5 β -pregnan-3 α ,20 α -diol	0
5 β -pregnan-3 α -ol-20-one	9
5 α -pregnan-20-dimethyl-3 α ,20-diol	0

Table 3. Inhibition of ^3H -Aldosterone Binding to Hippocampal Mineralocorticoid Receptors

Competitor (10^{-6}M)	% of Inhibition
Aldosterone	95.5
5 α -pregnan-3 α ,21-diol-20-one	76.7
5 β -pregnan-3 α ,21-diol-20-one	13.8
5 α -pregnan-3 α ,ol-20-one	0
5 β -pregnan-3 α ,ol-20-one	0
5 α -pregnan-3 α ,20 α -diol	0
5 β -pregnan-3 α ,20 α -diol	0
5 α -pregnan-3 α ,20-diol-20-dimethyl	0
5 α -pregnan-3 α ,ol-3 β -methyl-20-one	3.2
5 α -pregnan-3 β ,20-trimethyl-3 α ,20-diol	0

-79-

For Table 4, brain cytosol fractions were prepared as for Table 3, and the compounds were incubated with 3 nM of ^3H -dexamethasone (the specific ligand for the glucocorticoid receptor).

Table 4. Inhibition of ^3H -Dexamethasone Binding to Glucocorticoid Receptors

Competitor (10^{-6}M)	% of Inhibition
Dexamethasone	100
5 α -pregnan-3 α ,21-diol-20-one	29.5
5 β -pregnan-3 α ,21-diol-20-one	8.2
5 α -pregnan-3 α -ol-20-one	8.7
5 β -pregnan-3 α -ol-20-one	5.9
5 α -pregnan-3 α ,20 α -diol	2.6
5 β -pregnan-3 α ,20 α -diol	1.4
5 α -pregnan-20-dimethyl-3 α ,20-diol	2.6
5 α -pregnan-3 α -ol-3 β -methyl-20-one	0.6

Table 5 shows the inhibition of ^3H -estradiol (the specific ligand for the estrogen receptor) binding to bovine uteri cytosol, prepared as previously described (Gee, *et al.* 1988). ^3H -Estradiol (0.15 nM) was incubated with the cytosol in the presence of the compounds.

5 **Table 5. Inhibition of ^3H -Estradiol Binding to Bovine Uteral Estrogen Receptors**

	Competitor (10^{-6}M)	% of Inhibition
	17 β -estradiol	100
	5 α -pregnan-3 α -ol-20-one	0
10	5 α -pregnan-3 α ,21-diol-20-one	2
	5 α -pregnan-3 α ,20 α -diol	0
	5 α -pregnan-3 α -ol-3-methyl-20-one	0
	5 β -pregnan-3 α ,21-diol-20-one	0
	5 α -pregnan-3 β ,20-trimethyl-3 α ,20-diol	0
15	5 β -pregnan-3 α ,20 α -diol	8
	5 β -pregnan-3 α -ol-20-one	0
	5 α -pregnan-20-dimethyl-3 α ,20-diol	0

20 The results of these experiments clearly show that neuroactive steroids do not have a strong affinity for any of the above steroid receptors. Thus, they will not have predicted hormonal side-effects which would result from such steroid receptor binding.

Anti-Convulsant Activity

25 Experiments were also performed to determine the physiological relevance of neuroactive steroid and GABA receptor interactions by assessing the ability of the compounds of and used in the invention to prevent metrazol induced convulsions in mice. Mice were injected with various doses of the

test compounds of the invention, 10 minutes prior to the injection of metrazol. The time to onset of myoclonus (presence of forelimb clonic activity) induced by metrazol was determined by observing each mouse for a period of 30 minutes. In control mice, metrazol (85 mg/kg) will induce convulsion in 95 % of the animals. The ability of several compounds of and used in the invention to protect mice from convulsion is shown in Table 6.

Table 6: Antimetrazol Activity of Neuroactive Steroids in Mice

Name	Route	Vehicle	Dose (mg/kg)	% Protected
3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one	IP	50 % hpbcd	10	75
3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-19-nor-5 β -pregnan-20-one	IP	50 % hpbcd	10	100
3 β -(4'-Carboxyphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one ethyl ester	IP	50 % hpbcd	10	18.75
3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50 % hpbcd	10	100
3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	50 % hpbcd	10	75
3 β -(4'-Acetoxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50 % hpbcd	10	100
3 α -Hydroxy-3 β -(3'-methoxy-1'-propynyl)-5 β -pregnan-20-one	IP	50 % hpbcd	10	75
3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one	IP	50 % hpbcd	1	87.5
3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one	IP	50 % hpbcd	10	75
3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemsuccinate salt	PO	water	10	80
3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemsuccinate salt	PO	water	10	75
3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-11,20-dione	IP	50 % hpbcd	10	50
3 β -[3-(2-propynyloxy)propyn-1-yl]-3 α -hydroxy-5 β -pregnan-20-one	IP	50 % hpbcd	10	50
3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 α -pregnan-20-one	IP	50 % hpbcd	10	50
3 α -Hydroxy-3 β -(5'-oxo-1'-hexynyl)-5 β -pregnan-20-one cyclic 5'-(1,2-ethanediyl acetal)	IP	50 % hpbcd	10	50

Name	Route	Vehicle	Dose (mg/kg)	% Protected
3 β -(4'-Biphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	dmso	10	0
3 β -(5-Acetylthien-2-yl)ethynyl-3 α -Hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 β -(4'-Trifluoromethylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	dmso	10	25
3 β -(4'-Chlorophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	dmso	10	37.5
3 β -(5'-Hydroxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 α -Hydroxy-3 β -(thien-2-yl)ethynyl-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
3 β -(3'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	75
3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	87.5
3 β -(4'-Cyanophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	43.7
3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one 4'-hemisuccinate sodium salt	IP	water	10	87.5
3 α -Hydroxy-3 β -[3'-(1H-pyrazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 α -Hydroxy-3 β -(4'-methylphenyl)ethynyl-5 β -pregnan-20-one	IP	50% hpbcd	10	75
3 α -Hydroxy-3 β -(6-oxo-1-heptynyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	62.5
3 β -(5'-Acetoxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 α -Hydroxy-3 β -(2'-pyridylethynyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
3 α -Hydroxy-3 β -(5'-oxo-1-hexynyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 β -(4'-Cyano-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 α -Hydroxy-3 β -(3'-hydroxypropynyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 α -Hydroxy-3 β -[3'(RS)-hydroxybutynyl]-5 α -pregnan-20-one	IP	50% hpbcd	10	50
3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 β -pregnan-20-one 4'(R/S)-hemisuccinate sodium salt	IP	water	10	50
3 β -(5'-Cyanopentynyl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 α -pregnan-20-one	IP	50% hpbcd	10	25

Name	Route	Vehicle	Dose (mg/kg)	% Protected
3 α -Hydroxy-3 β -[3'(RS)-hydroxybutynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 β -(5'-Hydroxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate sodium salt	IP	50% hpbcd	10	37.5
3 β -(3'-Acetoxypropyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 α -Hydroxy-3 β -(2'-methoxyphenyl)ethynyl-5 β -pregnan-20-one	IP	dmsO	10	12.5
3 β -(6'-Acetoxylhexyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
3 α -Hydroxy-3 β -[3'-(pyrid-4-yloxy)-1'-propynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 β -[2-(3',4'-Dimethoxyphenyl)ethyl]-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5
3 β -(3'-Hydroxy-3'-methylbutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	43.7
3 α -Hydroxy-3 β -[3'-(1H-1,2,3-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	25
3 α -Hydroxy-3 β -[3'-(1H-1,2,4-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	50% hpbcd	10	10
Sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl)thiosulfate	IP	water	10	37.5
Sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl)thiosulfate	IP	water	10	62.5
Sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-5 β -pregnan-20-on-21-yl]thiosulfate	PO	water	40	33.3
Sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl)thiosulfate	IP	water	10	62.5
Sodium S-(3 α -hydroxy-3 β -trifluoromethyl-19-nor-5 β -pregnan-20-on-21-yl)thiosulfate	IP	water	40	37.5
3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one hemisuccinate sodium salt	IP	50% hpbcd	10	50
3 α -hydroxy-21-(2'H-1,2,3,4-tetrazol-2'-yl)-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
3 α -Hydroxy-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one	IP	50% hpbcd	10	100
3 α -Hydroxy-21-[1H-(4-methyl-5-carboxyl)imidazol-1-yl]-5 β -pregnan-20-one ethyl ester	IP	50% hpbcd	10	37.5
21-[1'-(4,5-Dichloro)imidazolyl]-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
3 α -Hydroxy-21-(1'-imidazolyl)-5 α -pregnan-20-one	IP	50% hpbcd	10	50
3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	12.5

Name	Route	Vehicle	Dose (mg/kg)	% Protected
3 β -Ethinyl-3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	50
3 α -Hydroxy-21-(1H-3,5-dimethylpyrazolyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	50
3 α -Hydroxy-21-(1'-imidazolyl)-3 β -methyl-5 α -pregnan-20-one	IP	50% hpbcd	10	75
3 β -Ethinyl-3 α -Hydroxy-21-(1'-pyrazolyl)-5 β -pregnan-20-one	IP	50% hpbcd	10	62.5
3 α -Hydroxy-21-(1'-pyrazolyl)-3 β -methyl-5 α -pregnan-20-one	IP	50% hpbcd	10	87.5
3 α -Hydroxy-21-(pyrazol-1-yl)-5 β -pregnan-20-one	IP	50% hpbcd	10	62.5
3 α -Hydroxy-3 β -methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one	IP	50% hpbcd	10	87.5
3 α -Hydroxy-21-(1',2',4'-triazol-1-yl)-5 β -pregnan-20-one	IP	50% hpbcd	10	37.5
21-[1'-(4,5-Dicyano)imidazolyl]-3 α -hydroxy-5 β -pregnan-20-one	IP	50% hpbcd	10	50
3 α -Hydroxy-21-[1H-(2-methyl)imidazol-1-yl]-5 β -pregnan-20-one	IP	50% hpbcd	10	6.2
3 α -Hydroxy-21-(1'-pyrazolyl)-3 β -trifluoromethyl-5 β -19-nor-pregnan-20-one	IP	50% hpbcd	10	12.5
3 α -Hydroxy-21-(1'-imidazolyl)-3 β -trifluoromethyl-5 β -19-nor-pregnan-20-one	IP	50% hpbcd	10	50

The ability of neuroactive steroids to protect animals against other chemical convulsants was further demonstrated for 3 α -hydroxy-5 α -pregnan-20-one, 3 α ,21-dihydroxy-5 α -pregnan-20-one and 3 α -hydroxy-3 β -methyl-5 α -pregnan-20-one. The anticonvulsant tests are similar to that described above. The following chemical convulsants are: metrazol (85 mg/kg); (+)bicuculline (2.7 mg/kg); picrotoxin (3.15 mg/kg); strychnine (1.25 mg/kg); or vehicle (0.9% saline). Immediately after the injection of convulsant or vehicle, the mice were observed for a period of 30 to 45 minutes. The number of animals with tonic and/or clonic convulsions was recorded. In the maximal electroshock test, 50 mA of current at 60 Hz was delivered through corneal electrodes for 200 msec to induce tonic seizure. The ability of compounds to abolish the tonic component was defined as the endpoint. General CNS

-85-

depression potential was determined by a rotorod test 10 minutes after the injection of compounds where the number of mice staying on a rotating (6 rpm) rod for 1 minute in one of the three trials was determined. The ED₅₀ (the dose at which the half-maximal effect occurs) was determined for each screen and are presented in Table 7, *infra*. The results demonstrate that neuroactive steroids, in comparison to other clinically useful anti-convulsants, are highly effective with profiles similar to that of the BZ clonazepam. These observations demonstrate the therapeutic utility of these compounds as modulators of brain excitability, which is in correspondence with their high affinity interaction with the GR complex *in vitro*.

Table 7. Anticonvulsant Activity of Exemplified Neuroactive Steroids and those of Selected Clinically Useful Anticonvulsants in Mice

ED ₅₀ (mg/Kg)						
Compound	RR	MES	MTZ	BIC	PICRO	STR
3α5α ^(a) -P	30	28.6	4.9	12.3	10.2	> 300
5α-THDOC ^(a)	22.9	26.7	8.1	17.8	5.6	> 300
3α-hydroxy-3β-methyl-5α-pregnan-20 one ^(b)	246.2	> 100	6.3	61.9	35.4	> 100
Clonazepam*	0.184	93	0.009	0.0086	0.043	NP
Phenobarbital*	69	22	13	38	28	95
Phenytoin*	65	10	NP	NP	NP	**
Progabide***	--	75	30	30	105	75
Valproate*	426	272	149	360	387	293

The abbreviations are RR (Rotorod); MES (maximal electroshock); MTZ (metrazol); BIC (bicuculline); PICRO (picrotoxin); STR (strychnine); NP (no protection)

^(a) Dissolved in 20% hydroxypropyl-β-cyclodextrin in water. The route of administration for steroids and convulsants was i.p. and s.c., respectively.

* Anticonvulsant data are from Swinyard & Woodhead, General principles: experimental detection, quantification and evaluation of anticonvulsants, in *Antiepileptic Drugs*, D.M. Woodbury, J.K. Penry, and C.E. Pippenger, eds. p. 111, (Raven Press, New York), 1982.

^(b) Vehicle contained 0.32% hydroxypropylmethyl cellulose and 4% tween 80 in saline.

** Maximum protection of 50% at 55-100 mg/kg.

*** The chemical convulsants in the progabide studies were administered i.v., all data from Worms *et al.*, Gamma-aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra, *Journal of Pharmacology and Experimental Therapeutics* 220: 660-671 (1982).

Anxiolytic Effects

The following experiments demonstrate that the progesterone metabolites, 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one are effective anxiolytics in four animal models of human anxiety that measure the behavioral effects of anxiolytic compounds. It is to be understood that these two compounds describe the invention by way of illustration. Data on their synthetic derivatives in these measurements also is presented in Tables 8-10. The four animal models used to measure the behavioral effects of anxiolytic compounds are: 1) light/dark transition test; 2) elevated plus-maze; 3) Geller-Seifter conflict test and 4) Vogel test.

a) Light/dark Transition Test

The light/dark transition test (Crawley and Goodwin, "Preliminary report of a simple animal behavior model for the anxiolytic effect of benzodiazepines", *Pharmacol. Biochem. Behav.* 13:67-70 (1980)) is based on the observation that rodents naturally tend to explore novel environments, but open, brightly lit arenas are aversive to the rodents and inhibit exploratory behavior (Christmas and Maxwell, "A comparison of effects of some benzodiazepines and other drugs on aggressive and exploratory behaviour in mice and rats", *Neuropharmacol.* 9:17-29 (1970); File, "The use of social interaction as a method of detecting anxiolytic activity of chlordiazepoxide-like drugs", *J. Neurosci. Meth.* 2:219-238 (1980)). A variety of clinically established anxiolytics including diazepam, clonazepam and pentobarbital have been shown to increase the number of transitions between the light box and the dark box, whereas non-anxiolytic drugs do not demonstrate this behavioral effect (Crawley *et al.*, "Absence of intrinsic antagonist actions of benzodiazepine antagonists on an exploratory model of anxiety in the mice", *Neuropharmacol.* 23:531-537 (1984)).

Male N.I.H. Swiss-Webster mice (Harlan, Harlan, Indianapolis, IN) weighing 15-20 g were housed four per cage in polyethylene cages with sawdust bedding. The colony room was environmentally controlled (22°C) with a 12 hr light/dark cycle (0600-1800 hr). Food and water were available *ad libitum*, except during testing. The experiments were run from 0700-1500 hr and groups were counterbalanced for time of day effects. Mice were only administered drug or vehicle once.

The method used was a modification of methods previously described (Wieland *et al.*, "Anxiolytic activity of progesterone metabolite 5 α -pregnan-3 α -ol-20-one", *Br. Res.* 565:263-268 (1991)). The apparatus included two 2-compartment automated test chambers (Model RXYZCM16, Omnitech Electronics, Columbus, OH). The open compartment was connected to the enclosed compartment via a 7.5 x 7.5 cm passageway. The open compartment was brightly lit using a 200 W incandescent light bulb. The experimental room was kept dark. Interruptions of the infrared beams in either chamber were automatically recorded by being linked to a computer through a Digiscan Analyzer (Omnitech Electronics) and the data was analyzed using the Integrated Lab Animal Monitoring System (Omnitech Electronics). N.I.H. Swiss-Webster mice were administered vehicle or test drug intraperitoneally (IP), 10 min later they were placed in the center of the lit compartment. The number of transitions between the lit and dark chambers, total activity in the lit chamber and the time spent in the lit chamber were measured during a 10 min test period.

Figure 8 shows the effects of 3 α -OH-5 α -pregnan-20-one and 3 α -OH-5 β -pregnan-20-one in the light/dark transition test. Both compounds produced a significant dose-response curve in relation to the number of transitions between the dark box and the light box. Post-hoc comparisons showed that the number of the crossing for doses for both 3 α -OH-5 α -pregnan-20-one and 3 α -OH-5 β -pregnan-20-one were significantly increased at doses tested from control (Dunnett's t-test).

In addition both 3 α -OH-5 α -pregnan-20-one and 3 α -OH-5 β -pregnan-20-one produced significant ($p < 0.01$) increases in activity at 10 & 20 mg/kg as compared to control groups (Dunnett's t-test). There were no significant differences between the two compounds at any dose tested.

5 **b) *Elevated Plus-Maze***

The theoretical basis for the elevated plus-maze test is similar to that of the light/dark transition test. As it was described previously (Pellow *et al.* "Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat", *J. Neurosci. Meth.* 14:149-167 (1985)), the elevated plus-maze apparatus is designed to utilize the mice's natural aversion to open spaces. The apparatus consists of two open-arms and two enclosed-arms. The elevated plus-maze test allows for two measures of anxiety, the number of entries into the open-arms and the time spent on the open-arms, both expressed as a percentage of the total number of entries and time spent in/on both the open-arms and enclosed-arms.

15 Male N.I.H. Swiss-Webster mice (Harlan, Indianapolis, IN) weighing 15-20 g were housed four per cage in polyethylene cages with sawdust bedding. The colony room was environmentally controlled (22°C) with a 12 hr light/dark cycle (0600-1800 hr). Food and water were available *ad libitum*, except during testing. The experiments were run from 0700-1500 hr and groups were counterbalanced for time of day effects. Mice were only administered drug or vehicle once.

20 The method used was previously described (Lister, "The use of Plus-Maze to measure anxiety in the mouse", *Psychopharmacol.* 92:180-185 (1987)). The apparatus included two open arms perpendicular to two enclosed arms elevated 50 cm from the floor. Each arm was 50 cm long and the walls of the enclosed arms were 40 cm tall. The maze was made completely of black plexiglass. Incandescent 200 W light bulbs were above each of the open

arms to produce a strong contrast between the open arms and the enclosed arms.

Ten minutes after an injection, the N.I.H. Swiss-Webster mice were placed in the center of the plus-maze facing an open arm. During the 5 min test period, the number of entries onto the open arms and the enclosed arms, and the time spent in the open arms and enclosed arms were measured. All four paws had to be within an arm for the dependent variable to be measured. Therefore, the time spent in the center of the maze is not counted, so the total time spent in the open arms and the enclosed arms may not equal 5 min. The effects of 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one in the elevated plus-maze test are shown in Figure 9A. Both compounds demonstrate increase proportion of entries into the open-arms across doses. 3α -OH- 5α -pregnan-20-one produced significant increase in entries at 20 mg/kg ($p \leq 0.05$), whereas 3α -OH- 5β -pregnan-20-one produced significant increases in entries at 5 mg/kg ($p \leq 0.05$), 7.5 mg/kg ($p \leq 0.01$), and 10 mg/kg ($p \leq 0.01$).

In addition, 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one produced dose-dependent increases in the time spent in the open-arms (Fig. 9B). 3α -OH- 5α -pregnan-20-one produced significant increases in time spent on the open-arms at 10 mg/kg ($p \leq 0.01$), whereas 3α -OH- 5β -pregnan-20-one produced significant increases in time spent on the open-arms at 7.5 mg/kg ($p \leq 0.01$) and 10 mg/kg ($p \leq 0.01$).

Table 8 shows the summary of anxiolytic activities of compounds of and used in the invention using the elevated plus-maze under the same conditions described above.

Table 8: Anxiolytic Activity in Plus Maze in Mice

	Name	Route	Dose mg/kg	Vehicle	% Control
5	3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-5 α -pregnan-20-one	IP	10	50% hpbcd	175.7
	3 β -(4'-Acetylphenyl)ethynyl-3 α -hydroxy-19-nor-5 β -pregnan-20-one	IP	10	50% hpbcd	191
	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	141
10	3 β -(4'-Acetoxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	159
	3 α -Hydroxy-3 β -(3'-methoxy-1'-propynyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	134
	3 β -[3-(2-Propynyloxy)propyn-1-yl]-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	178
15	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 α -pregnan-20-one	IP	10	50% hpbcd	186
	3 β -(4'-Biphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	10	dms0	111
20	3 β -(5-Acetylthien-2-yl)ethynyl-3 α -Hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	83
	3 β -(4'-Chlorophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	10	dms0	161
	3 β -(5'-Hydroxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	137
25	3 α -Hydroxy-3 β -(thien-2-yl)ethynyl-5 β -pregnan-20-one	IP	10	50% hpbcd	148
	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one	IP	1	50% hpbcd	150
30	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	115
	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemsuccinate salt	PO	10	water	166
	3 β -(4'-Acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemsuccinate salt	PO	10	water	248
35	3 β -(4'-hydroxy-1'-butynyl)-3 α -hydroxy-5 β -pregnan-11,20-dione	IP	10	50% hpbcd	119
	3 β -(3'-Acetylphenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	143
40	3 β -(4'-Cyanophenyl)ethynyl-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	169
	3 β -(4'-Hydroxybutyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one 4'-hemisuccinate sodium salt	IP	10	water	149
	3 α -Hydroxy-3 β -[3'-(1H-pyrazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	10	50% hpbcd	116

	Name	Route	Dose mg/kg	Vehicle	% Control
	3 α -Hydroxy-3 β -(4'-methylphenyl)ethynyl-5 β -pregnan-20-one	IP	10	50% hpbcd	148
	3 α -Hydroxy-3 β -(6-oxo-1-heptynyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	130.5
5	3 α -Hydroxy-3 β -(2'-pyridylethynyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	123
	3 β -(4'-Cyano-1'-butynyl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	184
10	3 α -Hydroxy-3 β -(3'-hydroxypropynyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	128
	3 α -Hydroxy-3 β -[4'(R/S)-hydroxypentynyl]-5 α -pregnan-20-one	IP	10	50% hpbcd	102
	3 α -Hydroxy-3 β -[3'(RS)-hydroxybutynyl]-5 β -pregnan-20-one	IP	10	50% hpbcd	137.7
15	3 β -(5'-Hydroxypentyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one 5'-hemisuccinate sodium salt	IP	10	50% hpbcd	155
	3 β -(3'-Acetoxypropyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	109
20	3 α -Hydroxy-3 β -(2'-methoxyphenyl)ethynyl-5 β -pregnan-20-one	IP	10	dms0	152
	3 β -(6'-Acetoxylhexyn-1'-yl)-3 α -hydroxy-5 β -pregnan-20-one	IP	10	50% hpbcd	206
	3 α -Hydroxy-3 β -[3'-(1H-1,2,3-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	10	50% hpbcd	116
25	3 α -Hydroxy-3 β -[3'-(1H-1,2,4-triazol-1-yl)-1'-propynyl]-5 β -pregnan-20-one	IP	10	50% hpbcd	122
	Sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl) thiosulfate	IP	10	50% hpbcd	143
30	Sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl) thiosulfate	IP	10	water	125
	Sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-5 β -pregnan-20-on-21-yl] thiosulfate	IP	10	water	135
	Sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl) thiosulfate	IP	10	water	126
35	Sodium S-(3 α -hydroxy-3 β -trifluoromethyl-19-nor-5 β -pregnan-20-on-21-yl)thiosulfate	IP	10	50% hpbcd	139
	3 α -hydroxy-21-(2'H-1,2,3,4-tetrazol-2'-yl)-5 β -pregnan-20-one	IP	10	50% hpbcd	117
40	3 α -Hydroxy-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one	IP	10	50% hpbcd	164
	3 α -Hydroxy-21-[1H-(4-methyl-5-carboxyl)imidazol-1-yl]-5 β -pregnan-20-one ethyl ester	IP	10	50% hpbcd	112
	3 α -Hydroxy-21-(1'-imidazolyl)-5 α -pregnan-20-one	IP	10	50% hpbcd	141

	Name	Route	Dose mg/kg	Vehicle	% Control
	3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	138
	3 β -Ethinyl-3 α -Hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	179
5	3 α -Hydroxy-21-(1H-3,5-dimethylpyrazolyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	128
	3 α -Hydroxy-21-(1'-imidazolyl)-3 β -methyl-5 α -pregnan-20-one	IP	10	50% hpbcd	144
	3 β -Ethinyl-3 α -Hydroxy-21-(1'-pyrazolyl)-5 β -pregnan-20-one	IP	10	50% hpbcd	180
10	3 α -Hydroxy-21-(1'-pyrazolyl)-3 β -methyl-5 α -pregnan-20-one	IP	10	50% hpbcd	154
	3 α -Hydroxy-21-(pyrazol-1-yl)-5 β -pregnan-20-one	IP	10	50% hpbcd	129
	3 α -Hydroxy-3 β -methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one	IP	10	50% hpbcd	153
15	3 α -Hydroxy-21-(1',2',4'-triazol-1-yl)-5 β -pregnan-20-one	IP	10	50% hpbcd	135
	3 α -Hydroxy-21-[1H-(2-methyl)imidazol-1-yl]-5 β -pregnan-20-one	IP	10	50% hpbcd	96

c) *Geller-Seifter Conflict Test*

This animal model of human anxiety utilizes a conditioned state of conflict in rats to ascertain the anxiolytic properties of drugs. Rats are conditioned to bar press for positive reinforcement under two schedules of behavior (Geller and Seifter, "The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat," *Psychopharmacologia* 1:482-492 (1960)). The first includes bar pressing under a variable ratio schedule without punishment. The second component is a fixed ratio schedule with each bar press resulting in a positive reinforcement and a punishment. The punished component produces a state of conflict within the animal. The unpunished component allows for the observation of any response depressant effects a drug may possess. An anxiolytic response would increase the punished responding without affecting the unpunished responding.

Male albino Sprague-Dawley rats (Charles River Labs, Wilmington, MA) weighing 250-300 g were used for conflict experiments and were kept on a restricted diet of Purina Lab Chow food pellets with water available at all times to maintain body weight at 85% of their free-feeding young adult levels. Rats were housed individually under a 12-hour light-dark cycle with lights on from 0700-1900.

The anti-anxiety (punishment-lessening) and response depressant effects of 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one were measured in rats by the conflict test of Geller and Seifter (1960). In this 63-min test, hungry rats perform a lever-press response to obtain a sweetened milk reward. The reinforcement schedule consists of punishment and nonpunishment components, alternating approximately every 15 min. Rats were trained in test chambers (Coulbourn instruments) with a lever mounted in one wall, a small dipper that delivered the 0.1-mL milk reward (1 part Eagle condensed : milk 2 parts water), and a metal grid floor through which the foot-shock punishment was administered. A DEC PDP 11/73 minicomputer running SKED (State Systems) was used for programming and recording.

Rates initially learned to respond on a continuous reinforcement schedule and progressed rapidly to 30-sec, 1-min, and 2-min variable interval (VI) schedules. On the continuous reinforcement schedule, rats received milk reward following every lever press; on the VI schedules, milk rewards were available at infrequent and variable intervals, eventually at an average of once every 2 min. Four 3-min "conflict" periods were then introduced on the unpunished VI baseline; the first started after 3 min of VI performance and the others were alternated between 12-min periods of VI responding. During conflict periods, which were signalled by the presentation of a light and a tone, the continuous reinforcement schedule was again in force and each lever press delivered both a milk reward and a brief (0.25 msec) foot-shock punishment. Shock intensity was 0.2 mA initially, and was increased daily in increments of 0.02 mA in order to gradually suppress lever pressing to 5 responses or less per conflict period. This training took 4-6 weeks, after

which stable low rates of response were observed during conflict periods and stable high rates in the nonpunishment periods. Drug-induced increases in the rate of punished responses were taken as an index of antianxiety activity, while decreases in the rate of unpunished responses were taken as an index of response depression or sedation.

The effects of 3α -OH- 5α -pregnan-20-one and 3α -OH- 5β -pregnan-20-one in the conflict test are summarized in Figure 10. Both compounds produced large increases in the rate of punished responses, suggesting that both would be active as antianxiety agents. The peak effect of 3α -OH- 5β -pregnan-20-one was observed at 2 mg/kg and that of 3α -OH- 5α -pregnan-20-one at 4.4 mg/kg following subcutaneous administration. (For statistical analysis and because of the small number of tests at each dose, all tests with each compound were combined for comparison against vehicle control tests, using a t-test for related measures: for 3α -OH- 5α -pregnan-20-one, $p < 0.02$; for 3α -OH- 5β -pregnan-20-one, $p < 0.008$).

Table 9 shows the summary of anxiolytic activities of compounds of and used in the invention using Geller-Seifter test under the experimental conditions described above.

Table 9. Anxiolytic Activity in Geller/Seifter in Rats

Compounds	Route	Vehicle	Dose (mg/kg)	Geller/Seifter (% of control)
3 α -Hydroxy-3 β -methoxymethyl-5 α -pregnan-20-one	IP	50% hpbcd	10	958
11 α -N,N-Dimethylamino-3 α -hydroxy-3 β -trifluoromethyl-5 β -pregnan-20-one	IP	citrate	20	145
Sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl)thiosulfate	PO	water	32	4487.5
3 α -hydroxy-3 β -ethoxymethyl-5 α -pregnan-20-one	IP	50% hpbcd	40	3743

d) Vogel Test

The Vogel test is based on the development of a conflict between a highly motivated behavior and an aversion. For this test, the strong motivation is thirst. The animal is water deprived for 12-16 hrs to produce the motivation to drink. During the training period the animals are exposed to the testing environment so they become accustomed to the drinking spout and minimize the fear of a novel environment. Following training, the animals are allowed access to water for 2 hrs. During this time, the animals will drink and eat their normal amount of water and food, compensating for the deprivation time. However, this schedule still produces a strong motivation to drink during the testing period.

Having been deprived of water for twelve to sixteen hours, an animal is placed in a test cage where it is allowed to drink freely for five minutes. This period is used to habituate the animal to the environment and the drinking spout. Following the training period, animals have access to water and food

-97-

in their home cage for 2 hrs. Food is available at all times. Twenty-four hours later, drug is administered to the animal intracerebroventricularly.

5 After an indicated delay started from the time of injection the animal is again placed in the test cage for ten minutes. A computer counts each time the animal licks, and after every twentieth lick administers a mild electric stimulus across the tongue and/or feet. The electrical stimulus consists of a 0.6 mA current with a duration of 100 msec. This procedure produces a state of conflict for the animal that is reduced by the administration of clinically used anxiolytic agents (i.e., Valium). For dose-response curves, separate
10 groups of animals are injected with increasing doses of test drug and are tested at a predetermined time.

Data of representative compounds using these measurements are summarized in Table 10.

Table 10. Anxiolytic Activity in Vogel Test in Rats

	Compounds	Route	Vehicle	Dose ($\mu\text{g/kg}$)	Vogel (% of control)
5	3 α ,20 α -Dihydroxy-2 β -isopropoxy-5 α -pregnane	i.c.v.	g-CD	10	169.0
	3 α ,20-Dihydroxy-20-methyl-5 α -pregnane	i.c.v.	g-CD	20	179.0
	3 α ,20 α -Dihydroxy-21-methyl-5 α -pregnane	i.c.v.	g-CD	10	157.9
10	3 α ,20 α (S)-Dihydroxy-5 α -pregnane	i.c.v.	g-CD	10	193.0
	3 α -Hydroxy-5 α -pregnan-20-one	i.c.v.	g-CD	10	431.1
	3 α ,20 α -Dihydroxy-5 α -pregnane	i.c.v.	g-CD	10	283.3
15	2 β -Fluoro-3 α ,20 α -dihydroxy-5 α -pregnane	i.c.v.	g-CD	20	264.9
	3 α ,20 α -Dihydroxy-21-ethyl-5 α -pregnane	i.c.v.	g-CD	20	225.8
	3 α ,20 α -Dihydroxy-5 α -pregnane	i.c.v.	g-CD	20	267.3

Prodrugs

Anti-convulsant and anxiolytic activities of prodrugs of the basic compounds 3 α -hydroxy-5 α -pregnan-20-one and 3 α ,21-dihydroxy-5 α -pregnan-20-one and their derivatives were assessed as using the same procedures described above. Percent protection by several prodrugs of 3 α -hydroxy-5 α -pregnan-20-one against metrazol-induced seizures was plotted against time after administration of the compounds. (Fig. 11 and Table 11).

Modification of the basic compounds 3 α -hydroxy-5 α -pregnan-20-one and 3 α ,21-dihydroxy-5 α -pregnan-20-one at the 3 α and 21 hydroxyls with various esters maintains their biological activity and in some cases such modification increased the time of protection provided by the compound.

Thus, the compounds of this invention can be modified to provide anti-convulsant and anxiolytic activities over a period of time, with varying degrees of protection.

**Table 11. Anti-Metrazol Activity of Prodrug Esters of
3 α -Hydroxy-5 α -pregnane-20-one (3 α -(RCOO)-5 α -pregnan-20-one)**

R	% Protection 60 mg/kg 1 hr, IP
Methyl	25
Ethyl	75
Propyl	75
Butyl	33
2-Propyl	75
4-Heptyl	16 (4 hour)
Cyclobutyl	17
Phenyl	33
4-Chlorophenyl	50
4-Methoxyphenyl	17
3-Pyridyl	50 (20 hour)
3-(1-Methyl-1,4-dihydropyridinyl)	63 (20 hour)

In contrast to benzodiazepines, neuroactive steroids can also induce anesthesia. Their ability to induce anesthesia is thought to be due to their ability to open the chloride ion channel in the absence of GABA, which is a property not possessed by benzodiazepines. Therefore, neurosteroids can act directly in the absence of GABA, at the receptor, and also "indirectly", in the presence of GABA. This "indirect" action is called "modulating" the receptor. (Lambert, *et al.*, "Actions of synthetic and endogenous steroids on the GABA_A receptor," *Trends Pharmacology Science* 8: 224-227 (1987).)

-100-

5 The compounds of and used in the invention can also be used for anesthetic indications at high doses. However, the preferred route of administration to induce anesthesia is intravenous (i.v.) administration. In animals, a drug's anesthetic properties is measured by the drug's ability to produce a loss-of-righting reflex. The loss-of-righting reflex is defined as the inability of an animal to right itself within 30 seconds when placed on its back. Mice were administered drug i.v. in the lateral tail vein. Following administration, mice were placed on their backs and observed for loss-of-righting reflex. Illustrative results are presented in Table 12.

Table 12. Anesthetic Activity of Neuroactive Steroids in Mice

	Compounds	Route	Vehicle	Dose (mg/kg)	Loss-of-Righting Reflex
5	3 α ,21-Dihydroxy-3 β -ethynyl-5 β -pregnan-20-one	iv	20% cremophor	10	100
	3 β -(Chloroethynyl)-3 α -hydroxy-5 β -pregnan-20-one	iv	micronizing solution	20	100
	3 β -Ethynyl-3 α -hydroxy-5 β -pregnan-20-one	iv	10% hpbcd	30	100
10	3 α -Hydroxy-3 β -methyl-5 α -pregn-16-en-20-one	iv	micronizing solution	50	100
	3 α -Hydroxy-5 α -pregn-9-en-20-one	iv	micronizing solution	10	100
15	3 α -Hydroxy-17(Z)-methoxymethylene-19-nor-5 α -androstane	iv	micronizing solution	5	75
	3 α -Hydroxy-3 β -methyl-5 β -pregnan-20-one	iv	micronizing solution	2.5	100
20	2 β -Ethoxy-3 α -hydroxy-5 α -pregnan-20-one	iv	20% cremophor	5	100
	2 β -Fluoro-3 α -hydroxy-5 α -pregnan-20-one	iv	micronizing solution	5	100
25	3 α -Hydroxy-3 β -methyl-21-methoxymethyl-5 α -pregnan-20-one	iv	micronizing solution	20	100

It is anticipated that prodrugs, with similar modifications as described above, of compounds of and used in the invention will have activity as prodrugs of 3 α -hydroxy-5-reduced-pregnanes.


While the preferred embodiments have been described and illustrated, various substitutions and modifications may be made thereto without departing

-102-

from the scope of the invention. Accordingly, it is to be understood that the present invention has been described by way of illustration and not limitation.

What Is Claimed Is:

1. A compound of the formula:



wherein:

R is hydrogen, halogen, lower alkoxy, alkyl, optionally substituted 1-alkynyl or substituted alkyl;

R₁ is a substituted aralkynyl, arylalkyl, arylalkenyl, aryl, optionally substituted aralkylalkynyl, alkanoyloxyalkynyl, optionally substituted heteroaryloxyalkynyl, oxoalkynyl or a ketal thereof, cyanoalkynyl, optionally substituted heteroarylalkynyl, hydroxyalkynyl, alkoxyalkynyl, aminoalkynyl, acylaminoalkynyl, mercaptoalkynyl, hydroxyalkynyl dioic acid hemi-ester or a salt thereof, or alkynyloxyalkynyl;

R₂ is hydrogen, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, a keto group or amino group;

R₃ is an acetyl group, a ketal of an acetyl group; an alkoxyacetyl group, an alkylthioacetyl group, an alkylsulfinylacetyl group, an alkylsulfonylacetyl group, an aminoacetyl group, a trifluoroacetyl group; a hydroxyacetyl group; an alkoxyalkylacetyl group; a hydroxyalkyl group; a hydroxyacetyl dioic acid hemi-ester salt; an alkanoyloxyacetyl group; a sulfoxyacetyl group; an alkylacetyl group; a haloacetyl group; an ethynyl group; an optionally substituted heteroarylacetyl group; an optionally substituted heteroaralkylacetyl group which may also optionally be substituted

on the alkylene with a hydroxy, alkoxy, alkanoyloxy or carbalkoxyl group; an optionally substituted heterocyclic-acetyl group; an acetyl thiosulfate salt; a cyano group; a methylene group (together with R₇); an alkylmethylene group (together with R₇); or an alkoxymethylene group (together with R₇);

5 R₄ is hydrogen or methyl,

R₅ is hydrogen;

R₆ is hydrogen, alkanoyl, aminocarbonyl or alkoxycarbonyl;

10 R₇ is hydrogen, halogen, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, a methylene group (together with R₃), or an alkoxymethylene group (together with R₃);

R₈ is hydrogen or halogen;

R₉ is hydrogen, halogen, alkyl, alkoxy, arylalkoxy or amino; and

15 R₁₀ is hydrogen, halogen, alkyl, haloalkyl, hydroxy, alkoxy, alkanoyloxy, carbalkoxyl, cyano, thiocyno or mercapto;

with the proviso that when R₃ is an optionally substituted heteroarylacetyl group or an acetylthiosulfate salt or when R is an optionally substituted 1-alkynyl group, then R₁ may further be hydrogen, alkyl, alkenyl, aryl, aralkyl, alkynyl, optionally substituted aralkynyl, alkoxyalkyl, aminoalkyl, cyano, cyanoalkyl, thiocynoalkyl, or azidoalkyl;

20 or a physiologically acceptable 3-ester, 20-ester, 21-ester, 3,20-diester, or 3,21-diester thereof.

2. The compound of claim 1, wherein:

R is hydrogen, fluoro, chloro or lower alkoxy;

R₁ is substituted arylethynyl;

25 R₂ is hydrogen, a keto group or a dimethylamino group;

30 R₃ is a β -acetyl group, a dimethyl ketal of a β -acetyl group, a trifluoroacetyl group, a β -(hydroxyacetyl) group, a β -methoxymethylacetyl group, a β -(ethoxy)methyl-2'-methylene acetyl group, a β -(1'-hydroxyethyl) group, a β -(1'-hydroxypropyl) group, a β -(2'-hydroxy-2'propyl) group, a β -succinyloxyacetyl group, a β -hydroxyacetyl sodium succinate group, a β -

-105-

acetoxyacetyl group, a β -sulfoxyacetyl group, a β -methylacetyl group, a β -haloacetyl group, or a β -ethynyl group;

R_4 is hydrogen or methyl;

R_5 , R_6 , R_8 , R_9 and R_{10} are hydrogen;

5 the dotted lines all represent single bonds; and

R_7 is hydrogen or, when R_3 is β -hydroxyacetyl, R_7 is hydrogen or hydroxy.

3. A compound of claim 1, wherein R_1 is substituted arylethynyl.

4. A compound of claim 3 which is 3α -hydroxy- 3β -(4'-nitrophenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-methoxyphenyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -[2-(3',4'-dimethoxyphenyl)ethynyl]- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4'-methylphenyl)ethynyl- 5β -pregnan-20-one, 3β -(4'-trifluoromethylphenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3α -hydroxy- 3β -(2'-methoxyphenyl)ethynyl- 5β -pregnan-20-one, 3β -(4'-dimethylaminophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-acetylphenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-chlorophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-acetylphenyl)ethynyl- 3α -hydroxy- 5α -pregnan-20-one, 3β -(4'-carboxyphenylethynyl)- 3α -hydroxy- 5β -pregnan-20-one ethyl ester; 3α -hydroxy- 3β -(4'-acetoxyacetylphenyl)ethynyl- 5β -pregnan-20-one, or 3β -(4'-cyanophenyl)ethynyl- 3α -hydroxy- 5β -pregnan-20-one.

5. A compound of claim 3 which is 3β -(4'-acetylphenylethynyl)- 3α -hydroxy-19-nor- 5β -pregnan-20-one; 3β -(4'-carboxyphenylethynyl)- 3α -hydroxy-19-nor- 5β -pregnan-20-one ethyl ester; 3β -(4'-carboxyphenylethynyl)- 3α -hydroxy- 5α -pregnan-20-one ethyl ester; 3β -[4'-(N,N-diethylcarboxamido)phenyl]ethynyl- 3α -hydroxy- 5β -pregnan-20-one; 3β -(4'-acetoxyphenylethynyl)- 3α -hydroxy- 5β -pregnan-20-one; 3β -(4'-

acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one; 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one; 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 α -pregnan-20-one 21-hemsuccinate salt; or 3 β -(4'-acetylphenylethynyl)-3 α ,21-dihydroxy-5 β -pregnan-20-one 21-hemsuccinate salt.

5

6. A compound of claim 1, wherein R₁ is aralkyl.

7. A compound of claim 6 which is 3 α -hydroxy-3 β -benzyl-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(2'-phenylethyl)-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(3'-phenylpropyl)-5 β -pregnan-20-one or 3 α -hydroxy-3 β -[2-(3',4'-dimethoxyphenyl)ethyl]-5 β -pregnan-20-one.

10

8. A compound of claim 1 wherein R₁ is aryl.

9. A compound of the claim 8, which is 3 α -hydroxy-3 β -phenyl-5 β -pregnan-20-one.

10. A compound of claim 1 wherein R₁ is cyanoalkynyl.

15

11. A compound of claim 10, which is 3 α -hydroxy-3 β -(5'-cyano-1'-pentynyl)-5 β -pregnan-20-one or 3 α -hydroxy-3 β -(4'-cyano-1'-butynyl)-5 β -pregnan-20-one.

12. A compound of claim 1, wherein R₁ is oxoalkynyl.

13. A compound of claim 12 which is 3 α -hydroxy-3 β -[6'-oxo-1'-heptynyl]-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(7'-oxo-1'-octynyl)-5 β -pregnan-20-one; 3 α -hydroxy-3 β -(5'-oxo-1'-hexynyl)-5 β -pregnan-20-one, or 3 α -hydroxy-3 β -(5'-oxo-1'-pentynyl)-5 β -pregnan-20-one.

20

-107-

14. A compound of claim 1, wherein R_1 is hydroxyalkynyl or a physiologically acceptable ester thereof.

15. A compound of claim 14 which is 3β -(4'(R/S)-hydroxypentynyl)- 3α -hydroxy- 5β -pregnan-20-one, 3β -[5'-(R/S)-hydroxyhexynyl]- 3α -hydroxy- 5β -pregnan-20-one, 3β -(5'-hydroxy-1'-pentynyl)- 3α -hydroxy- 5β -pregnan-20-one, 3β -(5'-hydroxy-1'-pentynyl)- 3α -hydroxy- 5β -pregnan-20-one hemisuccinate sodium salt, 3β -(6'-hydroxy-1'-hexynyl)- 3α -hydroxy- 5β -pregnan-20-one, 3β -(6'-hydroxy-1'-hexynyl)- 3α -hydroxy- 5β -pregnan-20-one 6'-hemisuccinate sodium salt, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5β -pregnan-20-one, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5β -pregnan-20-one 4'-hemisuccinate sodium salt, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5α -pregnan-20-one, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5α -pregnan-20-one 4'-hemisuccinate sodium salt, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5β -19-norpregnan-20-one, 3β -(4'-hydroxy-1'-butynyl)- 3α -hydroxy- 5β -19-norpregnan-20-one 4'-hemisuccinate sodium salt, 3β -[3'(R/S)-hydroxy-1'-butynyl]- 3α -hydroxy- 5α -pregnan-20-one or 3β -(3'-hydroxy-1'-propynyl)- 3α -hydroxy- 5β -pregnan-20-one.

16. A compound of claim 1 wherein R_1 is alkanoyloxyalkynyl.

17. The compound of claim 16 which is 3β -(3'-acetoxy-1'-propynyl)- 3α -hydroxy- 5β -pregnan-20-one; 3β -(4'-acetoxy-1'-butynyl)- 3α -hydroxy- 5β -pregnan-20-one; 3β -(4'-acetoxy-1'-butynyl)- 3α -hydroxy- 5α -pregnan-20-one; 3β -(5'-acetoxy-1'-pentynyl)- 3α -hydroxy- 5β -pregnan-20-one; or 3β -(6'-acetoxy-1'-hexynyl)- 3α -hydroxy- 5β -pregnan-20-one.

18. A compound of claim 1, wherein R_1 is alkynyloxyalkynyl.

19. A compound of claim 18 which is 3α -hydroxy- 3β -[3-(2'-propynyloxy)-1-propynyl]- 5β -pregnan-20-one.

20. A compound of claim 1, wherein R_1 is alkoxyalkynyl.

21. A compound of claim 20 which is 3α -hydroxy- 3β -(3-methoxy-1-propynyl)- 5β -pregnan-20-one or 3α -hydroxy- 3β -(3-methoxy-1-propynyl)- 5α -pregnan-20-one.

5 22. A compound of claim 1, wherein R_1 is heteroaryloxyalkynyl.

23. A compound of claim 22 which is 3α -hydroxy- 3β -[3-(4'-pyridinyloxy)-1-propynyl]- 5β -pregnan-20-one.

24. A compound of claim 1, wherein R_1 is heteroarylalkynyl.

10 25. A compound of claim 24 which is 3α -hydroxy- 3β -(2'-thienyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(2-pyridyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -[3-(1'H-1,2,3-triazol-1'-yl)-1-propynyl]- 5β -pregnan-20-one; 3α -hydroxy- 3β -[3-(2'H-1,2,3-triazol-2'-yl)-1-propynyl]- 5β -pregnan-20-one, 3α -hydroxy- 3β -[3-(1'H-pyrazol-1'-yl)-1-propynyl]- 5β -pregnan-20-one, 3α -hydroxy- 3β -(5'-acetyl-2'-thienyl)ethynyl- 5β -pregnan-20-one, 3α -hydroxy- 3β -(3-pyridyl)ethynyl- 5β -pregnan-20-one, or 3α -hydroxy- 3β -(4-pyridyl)ethynyl- 5β -pregnan-20-one.

26. A compound of claim 1, wherein R_3 is an optionally substituted heteroarylacetyl group.

20 27. A compound of claim 26, wherein R_3 is an optionally substituted imidazolylacetyl group.

28. A compound of claim 27 which is 3α -hydroxy-21-(1'-imidazolyl)- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4-hydroxybutyn-1-yl)-21-(1-imidazolyl)- 5β -pregnan-20-one, 3α -hydroxy- 3β -(4-hydroxybutyn-1-yl)-21-(1-

imidazolyl)-5 β -19-norpregnan-20-one, 3 α -hydroxy-21-[1H-(4-methyl-5-carboxyl)imidazol-1-yl)-5 β -pregnan-20-one ethyl ester, 3 α -hydroxy-21-(1'-imidazolyl)-5 α -pregnan-20-one, 3 β -ethynyl-3 α -hydroxy-21-(1'-imidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'-imidazolyl)-3 β -methyl-5 α -pregnan-20-one, 3 α -hydroxy-21-[1H-(2-methyl)imidazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -trifluoromethyl-21-(1-imidazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-[1H-(2'-formyl)imidazol-1-yl]-5 β -pregnan-20-one, or 3 α -hydroxy-3 β -trifluoromethyl-21-(1-imidazolyl)-5 β -19-nor-pregnan-20-one.

29. A compound of claim 26, wherein R₃ is an optionally substituted pyrazolylacetyl group.

30. A compound of claim 29 which is 3 α -hydroxy-21-(pyrazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(pyrazol-1-yl)-5 α -pregnan-20-one, 3 α -hydroxy-21-(1H-3,5-dimethylpyrazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'-pyrazolyl)-3 β -methyl-5 α -pregnan-20-one, 3 α -hydroxy-21-(pyrazol-1-yl)-3 β -trifluoromethyl-5 β -pregnan-20-one, or 3 α -hydroxy-21-(pyrazol-1-yl)-3 β -trifluoromethyl-5 β -19-nor-pregnan-20-one.

31. A compound of claim 26, wherein R₃ is an optionally substituted triazolylacetyl group.

32. A compound of claim 31 which is 3 α -hydroxy-3 β -methyl-21-(1',2',4'-triazolyl)-5 α -pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-2-yl)-5 β -19-norpregnan-20-one, 3 α -hydroxy-21-(2H-1,2,3-triazol-2-yl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -methyl-21-(2'-H-1',2',3'-triazol-2'-yl)-5 α -pregnan-20-one, 3 β -ethynyl-3 α -hydroxy-21-(1',2',4'-triazolyl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -methyl-21-(1',2',3'-triazol-1'-yl)-5 α -pregnan-20-one, 3 α -hydroxy-21-(1',2',4'-triazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,4-triazol-1-yl)-5 β -pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1,2,3-triazol-1-yl)-5 β -

-110-

pregnan-20-one, 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(1H-1,2,3-triazol-1-yl)-5 β -19-norpregnan-20-one, 3 α -hydroxy-3 β -trifluoromethyl-21-(1H-1,2,3-triazol-1-yl)-5 β -19-norpregnan-20-one, or 3 α -hydroxy-3 β -trifluoromethyl-21-(1H-1,2,3-triazol-1-yl)-5 β -19-pregnan-20-one.

5 33. A compound of claim 26, wherein R₃ is an optionally substituted tetrazolylacetyl group.

 34. A compound of claim 33 which is 3 α -hydroxy-21-(2'H-1,2,3,4-tetrazol-2'-yl)-5 β -pregnan-20-one, 3 α -hydroxy-21-(1'H-1,2,3,4-tetrazol-1'-yl)-5 β -pregnan-20-one, or 3 α -hydroxy-3 β -(4-hydroxybutyn-1-yl)-21-(tetrazol-1-yl)-5 β -pregnan-20-one.

10

 35. A compound of claim 26, wherein R₃ is an optionally substituted benzimidazolylacetyl group.

 36. A compound of claim 35 which is 3 α -hydroxy-21-(1'-benzimidazolyl)-5 β -pregnan-20-one, 21-(1'-benzimidazolyl)-3 α -hydroxy-3 β -methyl-5 α -pregnan-20-one or 21-(1'-benzimidazolyl)-3 α -hydroxy-3 β -methyl-5 α -pregnan-20-one.

15

 37. A compound of claim 26, wherein R₃ is an optionally substituted purinylacetyl group.

 38. A compound of claim 37 which is 3 α -hydroxy-21-(9'H-purin-9'-yl)-5 β -pregnan-20-one or 3 α -hydroxy-21-(7'H-purin-7'-yl)-5 β -pregnan-20-one.

20

 39. A compound of claim 1, wherein R is a dialkylamino group and R₃ is an optionally substituted heteroarylacetyl group.

-111-

40. A compound of claim 39, wherein R is a morpholino group and R₃ is an optionally substituted triazolylacetyl group.

41. A compound of claim 40 which is 3 α -hydroxy-2 β -morpholinyl-21-(1,2,4-triazolyl)-5 α -pregnan-20-one.

5 42. A compound of claim 1, wherein R₃ is an optionally substituted uracilacetyl group.

43. A compound of claim 42, which is 3 α -hydroxy-21-(1'-uracil)-5 α -pregnan-20-one.

10 44. A compound of claim 1, wherein R is an optionally substituted 1-alkynyl group.

45. A compound of claim 1, wherein R₃ is an acetyl thiosulfate salt.

15 46. A compound of claim 45 which is sodium S-(3 α -hydroxy-5 α -pregnan-20-on-21-yl)thiosulfate; sodium S-(3 α -hydroxy-3 β -methoxymethyl-5 α -pregnan-20-on-21-yl)thiosulfate; sodium S-(3 α -hydroxy-5 β -pregnan-20-on-21-yl)thiosulfate; sodium S-[3 α -hydroxy-3 β -(4'-hydroxybutynyl)-5 β -pregnan-20-on-21-yl] thiosulfate; or sodium S-(3 α -hydroxy-3 β -trifluoromethyl-5 β -19-norpregnan-20-on-21-yl) thiosulfate.

20 47. A compound of claim 45 which is sodium S-(3 α -hydroxy-3 β -methyl-5 α -pregnan-20-on-21-yl)thiosulfate.

48. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

-112-

49. A method of modulating the GABA_A receptor-chloride ionophore complex in an animal subject through binding to the neurosteroid site on said complex, comprising administering to said animal subject an amount, effective to modulate said complex, of a compound of claim 1.

5 50. A method of treating or preventing stress or anxiety in an animal subject, comprising administering to said animal subject in need of such treatment an effective amount of a compound of claim 1.

10 51. A method of alleviating or preventing seizure activity in an animal subject, comprising administering to said animal subject in need of such treatment an effective amount of a compound of claim 1.

52. A method of alleviating or preventing insomnia in an animal subject, comprising administering to said animal subject in need of such treatment an effective amount of a compound of claim 1.

15 53. A method of alleviating or preventing PMS or PND in an animal subject, comprising administering to said animal subject in need of such treatment an effective amount of a compound of claim 1.

54. A method of treating or preventing mood disorders in an animal subject, comprising administering to said animal subject in need of such treatment an effective amount of a compound of claim 1.

20 55. The method of claim 54, wherein said mood disorder is depression.

56. A method of inducing anesthesia in an animal subject, comprising administering to said animal subject an effective amount of a compound of claim 1.

-113-

57. The method of any one of claims 49-56, wherein said compound is a pharmaceutically acceptable ester or diester of an acid selected from the group consisting of acetic, propionic, maleic, fumaric, ascorbic, pimelic, succinic, glutaric, bismethylenesalicylic, methanesulfonic, ethane-di-sulfonic, 5 oxalic, tartaric, salicylic, citric, gluconic, itaconic, glycolic, *p*-aminobenzoic, aspartic, glutamic, γ -amino-butyric, α -(2-hydroxyethylamino)-propionic, glycine and other α -amino acids, phosphoric, sulfuric, glucuronic, and 1-methyl-1,4-dihydronicotinic.

58. The method of any one of claims 49-56, wherein said effective 10 amount is from about 1 mg to about 100 mg per dosage unit when administered intravenously and from about 100 mg to about 500 mg per dosage unit when administered non-intravenously.

1/11




FIG. 1A




FIG. 1B

2/11




FIG. 2

3/11




FIG. 3

4/11




FIG. 4

5/11




FIG. 5

6/11




FIG. 6

7/11




FIG. 7

8/11




FIG. 8





FIG. 9B

10/11




FIG. 10

11/11




FIG. 11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01712

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/58, 31/56; C07J 43/00, 41/00

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/169, 172, 176, 177, 178, 179, 180, 181, 182; 540/94, 95, 96, 97, 98, 99, 106, 107, 108, 109, 110, 111, 112

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,232,917 (Bolger et al) 03 August 1993, see entire document.	1-58
A	US, A, 5,120,723 (Gee et al) 09 June 1992, see entire document.	1-58
A	US, A, 3,953,429 (Cook et al) 27 April 1976.	1-58

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 MAY 1995

Date of mailing of the international search report

19 JUN 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CECILIA TSANG

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01712

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

514/169, 172, 176, 177, 178, 179, 180, 181, 182; 540/94, 95, 96, 97, 98, 99, 106, 107, 108, 109, 110, 111, 112